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ABSTRACT 
 
 
Udan, Maria L.D. PhD., University of Missouri-Saint Louis, August 2009. Activation of 
the innate immune response by the Alzheimer’s amyloid beta protein via Toll-like 
receptors. Major Professor: Michael R. Nichols 
 
 
Alzheimer’s Disease (AD) is the most common form of neurodegenerative disease 
characterized by the generation and deposition of amyloid beta plaques and the formation 
of neurofibrillary tangles. A wealth of data now demonstrate that inflammation is a 
prominent feature in AD pathology and a potential therapeutic target for the treatment 
and prevention of the disease. The emergence of evidence linking amyloid beta protein 
(Aβ), the primary component of senile plaques, to inflammation has led to new insights 
into understanding AD pathology. Aβ, a protein fragment resulting from cleavage of 
human amyloid precursor protein (APP), primarily exists in two forms: a slower-
aggregating 40-amino acid long peptide (Aβ(1-40)), and a faster-aggregating 42-residue 
peptide Aβ(1-42). This investigation focused on elucidating the mechanism by which Aβ 
provokes an inflammatory response in AD. For this study, we utilized THP-1 human 
monocytes/macrophages as an inflammatory model system due to their sensitivity to Aβ. 
We hypothesized that fibrillar Aβ(1-42) may utilize Toll-like receptors (TLRs), a family 
of transmembrane receptors that mediate recognition of certain conserved structural 
motifs in pathogens, for production of proinflammatory products and activation of the 
innate immune response. Biophysical characterization of the bioactive species of Aβ(1-
42) revealed that a soluble yet fibrillar species of Aβ(1-42) invokes tumor necrosis factor 
alpha (TNFα) production in THP-1 monocytes/macrophages. Moreover, using a TLR 
antibody neutralization assay, whereby receptor blockade inhibits cell responsiveness to 
TLR ligands, we showed that both TLR2 and TLR4 were highly involved in Aβ(1-42)-
induced TNFα production. The role of TLR2 in Aβ-induced innate immune response was 
further substantiated by the production of proinflammatory interleukin-8 (IL-8) in 
transfected HEK293 cells, a mammalian cell line that does not express TLR2, after 
stimulation with Aβ(1-42). Furthermore, our results suggest the possible involvement of 
TLR2/TLR1 or TLR2/TLR6 for the Aβ-induced activation of TLR downstream 
signaling. Taken together, our findings provide strong correlation between Aβ and innate 
immune response activation via TLR2 and TLR4. The identification of TLRs that 
recognize Aβ has opened new venues for understanding the mechanism of Aβ-induced 
inflammatory response and may thus be a new therapeutic target for AD. 
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1 INTRODUCTION 
 
 
1.1 Alzheimer’s Disease: Comprehending the etiology of the disease 
 
Advances in scientific and medical research have resulted in a dramatic rise in 
human life expectancy. In the 20th century, an increasing number of individuals have 
reached the age at which short-term memory defects linked with normal aging of the 
human brain has become one of the major concerns. Although this is a common 
occurrence among older people, the problem arises when a person starts to have trouble 
following complex discussions and making decisions, and begins to experience a 
heightened degree of forgetfulness. These are common symptoms of dementia, an illness 
that is associated with age, in which parts of the brain begin to malfunction causing 
disruptions and progressive loss in memory, judgement, reasoning and behavioral 
stability (St George-Hyslop 2000).  
Alzheimer’s Disease (AD) is the most common form of neurodegenerative 
dementia. This illness currently affects about 10% of persons over 65 years of age, and 
>40% of people over 85 years (Buxbaum and Tagoe 2000). Globally, the disease affects 
almost 2% of the population in industrialized countries, and it is predicted that the 
occurrence of AD will increase three-fold within the next fifty years (http://www.alz.org). 
There is no strong correlation between the occurence of AD and race or sex type. 
However, it is more prevalent in women mainly due to the fact that women live longer 
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than men (Irvine, El-Agnaf et al. 2008). To date, there is still no definitive diagnosis of 
the disease other than postmortem analysis of the brain (Georganopoulou, Chang et al. 
2005). However, the effort to decipher the causes and mechanism of AD has gone a long 
way since its discovery in 1906 by Alois Alzheimer (Selkoe 2001). Studies done for the 
past decades have identified two proteins that comprise the classical neuropathological 
lesions that are diagnostic of AD: the neurofibrillary tangles and senile plaques.   
 
1.1.1 Neurofibrillary Tangles 
 
In an effort to better understand the pathology of AD, researchers have done post-
mortem analysis of the human AD brain. Examination of the degenerating neurons in the 
diseased brain regions showed the presence of nonmembrane-bound clusters of abnormal 
cytoplasmic fibers ~20-nm length, which are referred to as neurofibrillary tangles (Kosik, 
Joachim et al. 1986; Selkoe 1996; Selkoe 2001). Furthermore, rigorous 
immunocytochemical and biochemical analyses identified the microtubule-associated 
phosphoprotein tau as the main component of neurofibrillary tangles (Grundke-Iqbal, 
Iqbal et al. 1986; Kosik, Joachim et al. 1986; Selkoe 1996). In the neurons, tau proteins 
can be found predominantly in axons. Under normal conditions, tau exists as a highly 
soluble phosphorylated protein, which functions as a stabilizer and promoter of 
microtubule polymerization (Hanger, Anderton et al. 2009). Microtubules are important 
for providing routes where nutrients and other molecules can move through cells (St 
George-Hyslop 2000). However, excessive tau phosphorylation and overexpression was 
found to be the main cause of transformation of soluble tau into tangles. Moreover, 
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numerous studies using antibodies specific for various phosphor-tau epitopes have 
suggested that the disregulation of tau phosphorylation is due to the augmented activity 
of certain kinases, such as glycogen synthase kinase-3 (GSK-3), cyclin-dependent kinase 
5 (cdk5), casein kinase 1 (CK1) and cyclic AMP-dependent protein kinase (PKA), as 
well as inactivation of certain phosphatases (Selkoe 1996; Patrick, Zukerberg et al. 1999; 
Churcher 2006; Hanger, Byers et al. 2007; Hanger, Anderton et al. 2009). So far, one 
recent therapeutic strategy focuses on how to subtly regulate the activity of kinases. The 
activation of phosphatases as a therapeutic target seems unlikely due to still poorly 
understood mechanism and involvement of phosphatases in tau pathology (Hanger, 
Anderton et al. 2009). 
 
1.1.2. Senile plaques 
 
Another directly observable hallmark of AD is the presence of extracellular senile 
or amyloid plaques. These clusters of protein accumulate in the spaces between nerve 
cells and are present extensively in the hippocampus and the cerebral cortex region of the 
AD brain. Closer analysis showed that these plaques contain extracellular deposition of 
numerous proteins, the principal of which is amyloid β- protein (Aβ) (Selkoe 2001). 
Numerous studies have associated both the more common 40-amino acids long Aβ 
(designated as Aβ(1-40)) and the less common but faster aggregating 42-amino acids 
long Aβ(1-42) with AD. There are two forms of senile plaques that have been detected in 
the diseased brain: neuritic plaques and diffuse plaques. Neuritic plaques are compact and 
contain the fibrillar form of both Aβ(1-40) and Aβ(1-42). Further evidences revealed the 
  4
presence of reactive proinflammatory cells called microglia, as well as reactive 
astrocytes, along with the plaques (El Khoury, Moore et al. 2003). Swollen and deformed 
neurons in the vicinity of the plaques are also observed. Microscopic analysis of the 
diseased brain sections showed that the size (diameter) of neuritic plaques vary greatly, 
from 10 to >120 μm (Selkoe 2001). In contrast, diffuse plaques are composed exclusively 
of Aβ(1-42). These amorphous plaques are also observed in young individuals afflicted 
with Down’s syndrome before Alzheimer’s type-dementia is manifested (Irvine, El-
Agnaf et al. 2008). Moreover, immunohistochemical studies of patients with Down’s 
syndrome demonstrated the presence of diffuse plaques at an early age, but neuritic 
plaques only occur at a later age, along with the presence of abundant neurofibrillary 
tangles (Lemere, Blusztajn et al. 1996; Selkoe 2001). Due to these findings, scientists 
considered diffuse plaques to be precursors of the neuritic plaques, and thus called diffuse 
plaques as “preamyloid deposits”.  
 
1.2 Probing the molecular mechanism of AD: Focus on amyloid β- protein (Aβ) 
 
As mentioned previously, AD is characterized by progressive accumulation of Aβ 
protein in the brain sections, mainly in the cerebral cortex, hippocampus and other 
regions of the brain. To understand the protein’s involvement in the disease, it is crucial 
to fully comprehend the molecular mechanism of Aβ production. A major breakthrough 
in the study of Aβ and its connection with AD transpired when scientists effectively 
isolated plaque amyloid deposits from the diseased brain and successfully sequenced the 
Aβ protein (Selkoe 1996; Mattson 2004). This led to the identification of amyloid 
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precursor protein (APP) as the major source of Aβ (Selkoe 1998; Castellani, Lee et al. 
2008). The subsequent discussions below will focus on the mechanism of Aβ production, 
Aβ hypothesis, and structural studies of Aβ and how it contributes to AD pathogenesis.   
 
1.2.1 Amyloid precursor protein processing and generation of Aβ 
 
Extensive reviews have been written about the nature of the human amyloid 
precursor protein. APP was identified as the main source of Aβ that is implicated in AD. 
Numerous researchers like Dennis Selkoe of Harvard, Mark Mattson of U. Kentucky and 
Edward Koo of UC San Diego, among others, have focused on elucidating the nature and 
function of this type-1 integral membrane glycoprotein. The human amyloid precursor 
protein (APP), which is located on chromosome 21, is composed of a single membrane 
spanning domain, a large extracellular domain and a shorter (~47 amino acid) 
cytoplasmic COOH-terminal region (Selkoe 2001; Thinakaran and Koo 2008). Studies 
now show that approximately half of Aβ(1-40) or Aβ(1-42) sequence lies on the 
extracellular part of APP (Aβ amino acids 1-17, from amino acids 597-613 of APP that is 
695-amino acid long (APP-695)), while the other half, which contains hydrophobic 
residues, lies within the phospholipid bilayer (Mattson 1997). Among the numerous 
isoforms, the largest of the known APP splice forms is comprised of 770 amino acids 
(Suzuki and Nakaya 2008). This particular APP is expressed throughout the body, as well 
as in neurons. Increasing evidence suggests that APP is important in neuronal growth and 
survival, synaptic plasticity and cell adhesion (Buxbaum and Tagoe 2000; Mattson 2004; 
Thinakaran and Koo 2008). 
  6
A model of APP processing is illustrated in Figure 1.1 (Mattson 2004). APP 
trafficking involves transit from the endoplasmic reticulum to the plasma membrane 
where it undergoes post-translational modification. Afterwhich, APP is rapidly 
internalized and translocated back to secretory vesicles through endocytic and recycling 
compartments (Selkoe 1998; Thinakaran and Koo 2008). During this trafficking process, 
APP molecules can undergo specific proteolytic cleavage through the action of enzymes 
α, β and γ secretases to release the secreted products into the extracellular space. The 
likely APP cleavage sites by the secretase enzymes that are discussed in this section are 
based on the sequence of APP-695. The action of α secretase on APP was the first to be 
identified. Investigations showed that α secretase clips 12 amino acids NH2-terminal to 
the single transmembrane domain of APP (between amino acids 612 and 613, amino 
acids 16 and 17 of Aβ) (Sisodia, Koo et al. 1990). This cleavage releases the non-
amyloidogenic form secreted APPsα ectodomain from the cell surface, leaving an 83-
residue (APP83) COOH-terminal fragment in the membrane. This residue is further acted 
upon by γ-secretase (cleavage between amino acids 639 and 640 of APP-695, and at the 
COOH terminus of Aβ) to form a shorter 3 kDa peptide p3 into the extracellular space. 
Aside from the products produced through the action of α-secretase, alternate APP 
cleavage occurs 16 amino acids NH2-terminal to the α-cleavage site is mediated by β 
secretase (amino acid residues 596 and 597 of APP-695 that corresponds to the NH2 
terminus of Aβ) (Mattson 1997; Selkoe 1998; Selkoe 2001). Consequently, a smaller 
fragment (s)APPβ is released into extracellular milieu, retaining a 99-residue (APP99) 
COOH-terminal fragment that contains intact Aβ in the membrane. This COOH-terminal 
fragment can be further proteolytically cleaved by γ-secretase to generate an intact Aβ  
  7
 
 
 
  
 
 
 
 
 
Figure 1.1. Processing of Amyloid precursor protein (APP). (a) Cleavage of APP involves the 
activities of α-, β- (BACE1) and γ-secretase. α secretase cleavage results in the release of soluble 
non-amyloidogenic APP fragment (sAPPα) from the cell surface and leaves an 83-amino acid-C-
terminal fragment (C83). BACE cleavage leaves a 99-aa residue, which can be further processed 
by γ-secretase to generate and liberate a 39-42 residue amyloidogenic peptide. The 99-residue 
fragment can also be internalized and further processed by γ-secretase to produce Aβ (1-40)/(1-
42) in endocytic compartments. C99 cleavage by γ-secretase also liberates an APP cytoplasmic 
domain that can translocate to the nucleus for modulation of gene expression, i.e., induction of 
apoptotic genes. Processing of APP/C99 residue by caspases results in the production of 
neurotoxic peptide C31. (b) Amino acid sequence of Aβ(1-40) and Aβ(1-42). The bold italics 
represent the part of Aβ that lies partly outside the cell membrane and is being liberated upon 
cleavage of APP by α secretase  (Mattson 1997; Mattson 2004) 
(b)  Aβ (1-40):  DAEFRHDSGY  EVHHQKLVFF  AEDVGSNKGA  IIGLMVGGVV 
 
       Aβ (1-42):  DAEFRHDSGY  EVHHQKLVFF  AEDVGSNKGA IIGLMVGGVVIA 
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peptide 38-42 amino acid residues in length (Mastrangelo, Ahmed et al. 2006; Pearson 
and Peers 2006). Under normal conditions, APP cleavage by β and γ secretases typically 
results in the formation of 40-residue Aβ peptide. However, about 10% of the cleavage 
product is Aβ(1-42) (St George-Hyslop 2000). Because the nature of γ secretase has not 
been fully understood, further studies are still being done as to the site of cleavage of 
APP99 and APP83. However, several lines of evidence showed that considerable amount 
of Aβ(1-40) and Aβ(1-42) are made during internalization and internal processing of the 
APP COOH fragment (Mattson 1997; Selkoe 2001; Mattson 2004). The formed Aβ(1-40) 
or Aβ(1-42) is then released from the cell and has likelihood to form fibrils.  
The α secretase-catalyzed APP cleavage is believed to be the predominant 
processing pathway for APP and the APPsα have distinct extracellular functions. 
Numerous in vitro studies reveal increasing number of roles of sAPPα in neurons 
including cell survival (Mattson, Cheng et al. 1993; Ohsawa, Hirose et al. 1995), 
stimulation of neurite outgrowth (Clarris, Nurcombe et al. 1994; Ohsawa, Hirose et al. 
1995; Furukawa, Sopher et al. 1996), regulation of cell adhesion, and protection against a 
range of metabolic, excitotoxic and oxidative insults, among others (Mattson, Cheng et 
al. 1993; Smith-Swintosky, Pettigrew et al. 1994; Selkoe 1998).  
The cleavage by β-secretase also normally occurs to produce and release Aβ. 
Studies indicate that Aβ is being generated constitutively by normal cells in blood and 
cerebrospinal fluid (CSF) with normal concentrations in the low nanomolar range (3-8 
nM for CSF and under 500 pM in plasma) (Seubert, Vigo-Pelfrey et al. 1992; Motter, 
Vigo-Pelfrey et al. 1995; Scheuner, Eckman et al. 1996; Dumery, Bourdel et al. 2001; 
Ramsden, Plant et al. 2001). Thus, unaffected individuals normally produce and clear Aβ. 
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Additionally, the Aβ protein being normally generated is thought to have a normal 
physiological role. On the other hand, individuals afflicted with AD generate Aβ that 
forms ordered aggregates, which are deposited as amyloid plaques.  
 
1.2.2 Missense mutations in APP and other mutations cause autosomal dominant AD 
 
Familial AD (FAD) occurs in mid, rather than late, adulthood (Buxbaum and 
Tagoe 2000). Numerous studies of FAD cases reveal that early-onset AD (EOAD) is 
caused by mutations in APP and presenilin genes. These mutations affect the metabolism 
or stability of Aβ and cause autosomal forms of AD (Selkoe 1996; LaFerla, Green et al. 
2007).  
Several lines of evidence showed that mutations affecting the APP gene (Figure 
1.2 adapted from (Selkoe 2001)) are closely associated with AD by increasing local 
concentration and deposition of Aβ (1-42). Most of the mutations are located within the 
Aβ sequence or in regions of the β-APP gene that encode amino acids that lie 
immediately adjacent to the β- or γ-secretase cleavage sites (Chartier-Harlin, Crawford et 
al. 1991; Goate, Chartier-Harlin et al. 1991; Mullan, Crawford et al. 1992; Dumery, 
Bourdel et al. 2001). The following discussion enumerates some of the known missense 
APP mutations that are linked to familial or early-onset AD.  
A double mutation (APP∆NL) that alters Lys670Met671 in APP770 to asparagine 
and leucine, respectively, also known as Swedish mutation, can be found just adjacent to 
the site of β secretase cleavage and induces heightened β-secretase cleavage to produce 
more Aβ(1-40) and Aβ(1-42) (Citron, Oltersdorf et al. 1992; Mullan, Crawford et al. 
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Figure 1.2. APP mutations genetically linked to familial Alzheimer’s disease. The sequence 
within APP region that contains the Aβ and transmembrane region is shown in expanded form, 
with a single-letter amino acid code. The underlined residues represent the Aβ sequence. Arrows 
represent the cleavage sites for α, β and γ secretases. The vertical broken lines indicate the 
transmembrane region of the APP. Residues in yellow are the known sites for missense 
mutations, and residues in blue are the amino acids that replace the amino acids in original 
sequence. These are mutations identified in certain patients with familial Alzheimer’s disease. 
The three-digit numbers represent the residue number according to the APP-770 isoform. (Selkoe 
2001) 
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 1992; Selkoe 2001). On the other hand, the five mutation sites that occur just COOH-
terminal to the γ-secretase cleavage sites (some of which are London mutation 
(Val717Ile), Rouen mutation (Val715Met) and Florida mutation (Ile716Val)) seemingly 
have an enhancing effect on the production of Aβ(1-42) species (Goate, Chartier-Harlin 
et al. 1991). The mutations within the Aβ sequence enhance the aggregational properties 
of all Aβ species. For instance, Dutch mutation (Ala692Gly) results in formation of 
plaques and tangles associated with dementia, and severe hereditary cerebral hemorrhage 
with β-amyloidosis (Hendriks, van Duijn et al. 1992; Buxbaum and Tagoe 2000; Selkoe 
2001). Afflicted individuals show extensive amyloid deposition in vessel walls of 
cerebral cortex and leptomeninges (Levy, Carman et al. 1990). In general, vast evidences 
revealed that APP mutation increases Aβ(1-42) concentration by a factor of 1.5 to 1.9, 
while Aβ(1-40) concentration remains the same (Findeis 2007).  
Aside from APP mutations, mutations in presenilin 1 (PS1, found on chromosome 
14) and presenilin 2 (PS2, on chromosome 1) have also accounted for 30% to 40% of all 
cases of EOAD. Presenilins are expressed in brain and concentrated in neurons 
(Scheuner, Eckman et al. 1996; Uchihara, el Hachimi et al. 1996). More than 30 
mutations in PS1 and 2 in PS2 have been reported (Selkoe 1997) and they generally 
result in increase of Aβ1-42) production (Scheuner, Eckman et al. 1996; Buxbaum and 
Tagoe 2000). For instance, immunohistochemical analyses of brains of patients with 
Glu280Ala PS-1 mutation showed a greatly elevated Aβ(1-42), but not Aβ(1-40), levels 
in the cerebellum (Lemere, Blusztajn et al. 1996). Evidences also showed that mutations 
in gene encoding PS lead to a 1.5 to 3-fold increase in the relative abundance of plaques 
containing Aβ(1-42) peptides in FAD, compared with the levels in sporadic cases of AD 
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(Lemere, Blusztajn et al. 1996; Mann, Iwatsubo et al. 1996; Selkoe 2001). Moreover, the 
rate of Aβ(1-42) aggregation was significantly enhanced in the presence of PS mutation, 
compared to that of Aβ(1-40) peptide (Jarrett, Berger et al. 1993).  
Taken together, these genetic studies support the notion that the mutations in APP 
and PS lead to a significantly increased production of faster-nucleating Aβ variant Aβ(1-
42) (Jarrett, Berger et al. 1993), and further underscores the idea that the acceleration of 
amyloid fibril formation is critical for the study of AD (Selkoe 1997). 
As discussed in the previous section (1.1), neurofibrillary tangles that contain 
hyperphosphorylated tau proteins and Aβ-containing senile plaques are hallmark 
characteristic features of AD. Over the years, debate has ensued over whether there is a 
link between Aβ and tau abnormalities, and whether either contribute to the pathogenesis 
of the disease. Numerous evidences have demonstrated that mutations in both genes 
encoding APP and tau result in dementing illness. However, further inquiry of the 
molecular effects and characterizing the clinical signs and symptoms of these mutations 
clarified the significance of tau and Aβ in AD progression. APP mutations were proven 
to accelerate Aβ production (as discussed above), and these mutations have been linked 
to some cases of EOAD (Goate, Chartier-Harlin et al. 1991). EOAD, although rare, 
reflects the histological profile of plaques and tangles. Furthermore, clinical studies of 
EOAD showed a characteristic hippocampal-predominant dysfunction as well as 
dysfunction in other neocortical sites. In comparison, investigations focusing on 
mutations of gene encoding tau showed that although these mutations promoted tau 
hyperphosphorylation, they did not lead to AD. Instead, the mutations resulted in the 
development of fronto-temporal dementia (FTD), which is another type of dementia 
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different from AD and characterized by frontotemporal atrophy (Hutton, Lendon et al. 
1998). Furthermore, the presence of tangles that appear first in extrahippocampal sites 
and the absence of plaques make FTD histologically distinct from AD (Small and Duff 
2008). These genetic findings led to the proposed “amyloid hypothesis” that Aβ is the 
primary instigator for pathogenicity in AD, and its accumulation and elevation result in 
the hyperphosphorylation of tau and other clinical features of AD (Small and Duff 2008).  
 
1.2.3 Amyloid β- peptide 
 
As discussed previously, the heterogeneous cleavage property of β and γ secretase 
gives rise to a 39 to 42 amino acid long fragment of Aβ, with  40- residue peptide (termed 
Aβ(1-40)) and 42-residue peptide (Aβ(1-42)) as the most common. The presence of two 
additional amino acids in Aβ(1-42) has extensive consequence with regards to its 
tendency to aggregate and form fibrils, with the longer Aβ(1-42) having a faster 
aggregation rate and being more pathogenic (McLaurin, Yang et al. 2000; Castellani, Lee 
et al. 2008). In 1985, researchers purified and characterized the peptide from post-
mortem brain of AD patients. Using liquid chromatography and western blotting, 
Beyreuther’s group revealed that the Aβ peptides isolated from diseased patients are 4-5 
kDa in size (Masters, Simms et al. 1985).   
The presence of Aβ in individuals not afflicted with AD indicates that the protein 
has a role in the normal physiology of the central nervous system; but the normal 
function of Aβ is less understood as compared to its cytotoxic effects and its pathological 
role in AD. Nevertheless, numerous investigations have revealed some of the roles of this 
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APP fragment in the normal function of neuronal cells. Teng and co-workers suggested 
that the more predominant form Aβ(1-40) functions as an antioxidant (Teng and Tang 
2005). Aβ(1-40) was also shown to counteract the toxic effects of β and γ secretase 
inhibitors at concentration as low as 10 pM (Plant, Boyle et al. 2003). Further studies 
have demonstrated that both Aβ(1-40) and Aβ(1-42) were found to moderate potassium 
channels in neurons (Ramsden, Plant et al. 2001; Findeis 2007).   
Despite the normal physiological roles of Aβ, the main focus of investigations is 
the ability of this protein to form fibrils and its role in neurodegeneration. Increasing 
interest in structural and functional properties of Aβ led to a better understanding of this 
protein fragment. Numerous investigators have utilized various methods like circular 
dichroism (CD), nuclear magnetic resonance (NMR), Fourier Transform Infrared 
spectroscopy (FTIR) and microscopy techniques, among others, to extensively study the 
structure of Aβ and its formation of fibrils (Hilbich, Kisters-Woike et al. 1991; Shen and 
Murphy 1995; Nilsson 2004; Stromer and Serpell 2005).  
One challenge that researchers encountered in studying the structure of 
Alzheimer’s Aβ is the insolubility of the amyloid plaque, and as a result, the analysis of 
Aβ from the diseased brain proved to be extremely difficult (Serpell 2000). This 
prompted researchers to concentrate on Aβ fibrils that are formed in vitro.  In vitro 
structural prediction studies revealed that the fibrils were of varying lengths, about 6-8 
nm in diameter, and generally possess a parallel β-sheet conformation (as shown in 
Figure 1.3a and b) in which amino acids 41-42 of one peptide strand interact with amino 
acids 34-35 of the second peptide monomer (Lansbury, Costa et al. 1995; Mattson 1997;  
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Figure 1.3. Structural studies of Aβ. (a) Ribbon diagram of residues 9-40 of Aβ (1-40) showing 
two β-sheet per molecule. Parallel β-sheets also observed on cross-β motif. (b) Atomic 
representation of fibers, showing the length (in diameter) of about 6-8 nm. (c) Structure 
prediction of Aβ (1-42), showing residues with high propensity for β-sheet. Highly hydrophobic 
regions are also shown. (Serpell 2000; Tycko 2004)  
 
 
 
 
 
(a) 
(c) 
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Kowalewski and Holtzman 1999; Tycko 2004). For fibrils of relatively shorter peptides 
(15 residues or less), an antiparallel β-sheet structure was demonstrated (Lansbury, Costa 
et al. 1995; Balbach, Ishii et al. 2000; Tycko 2004). Moreover, analysis of soluble 
Aβ peptide uncovered amino acid characteristics that favor β-sheet conformation and 
revealed that C-terminal residues 28 to 40/42 have the highest probability for β-sheet 
formation, while residues 9 to 21 showed a lower probability for β-sheet. Further 
investigations showed that the propensity of residues 28 to 40/42 to form β-sheet is due to 
its highly hydrophobic property. Residues 17-21 also exhibit greatest hydrophobicity. 
Two predicted sites for β-turn in the peptide structure can be found between residues 6 to 
8, and 23 to 27 (Figure 1.3c) (Serpell 2000). 
Using X-ray diffraction, Kirschner et al. revealed the β-sheet conformation of the 
Aβ fibers, estimating the length to be 80Å long and about 40Å thick (Kirschner, 
Abraham et al. 1986). These measurements correspond to four pleated sheets, with 
approximately 16 hydrogen-bonds for each sheet. Halverson et al. (1990) correlated 
peptide insolubility with β-sheet conformation using Fourier Transform Infrared 
spectroscopy (FTIR) studies. His group reported that residue Aβ(34-42) possessed 
antiparallel stable β-sheet structure in the solid state (Halverson, Fraser et al. 1990). It 
was also shown that the residues 10 to 42 may form the β-sheet core of the fibrils, while 
fragments 1-9 were not required for fibril formation. Furthermore, this N-terminal region 
may be exposed on the surface of the fibers and may play a role in interaction between 
fibrils (Hilbich, Kisters-Woike et al. 1991). In addition, using electron microscopy, 
Aβ(14-23) was found to be the shortest N-terminal fragment capable of fibril formation, 
and that deletions or substitutions on this fragment completely abolished or impaired 
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fibril formation (Tjernberg, Callaway et al. 1999). This led to the conclusion that 
sequence 14 to 23 of Aβ forms the core of Aβ fibrils.  
As shown by evidences that are stated previously, Aβ is a normal product in the 
brain and cerebrospinal fluid of normal individuals. This signifies that Aβ itself does not 
lead to neurodegeneration. However, studies showed that the key to neuronal injury 
seems to lie on the aggregation state of Aβ. Moreover, the ability of synthetic Aβ to form 
fibrils in vitro may be influenced by various parameters such as variations in pH, 
temperature, buffers or solvent composition, presence of metals such as iron, copper and 
zinc, peptide concentration and peptide sequence (Fraser, Nguyen et al. 1991; Shen and 
Murphy 1995; Mattson 1997; Lansbury 1999; Serpell 2000; Walsh, Tseng et al. 2000; 
Nichols, Moss et al. 2005). The following discussion will focus on the study of amyloid β 
fibril formation in vitro. 
 
1.2.4 Amyloid β fibrillogenesis 
 
Why is the study of amyloid β fibrillogenesis relevant? It has been about a decade 
0since the amyloid-β cascade hypothesis was first proposed. According to this 
hypothesis, deposition and accumulation of fibrillar Aβ in brain tissues are the key 
causative agent that drives AD pathogenesis (Hardy and Selkoe 2002; Teng and Tang 
2005; Castellani, Lee et al. 2008). This led to an increased interest on understanding Aβ 
fibril formation and how it can be a key to developing therapeutic strategies. Though 
numerous studies have focused on the biophysical aspects affecting formation of Aβ 
fibrils, the kinetics or mechanism of Aβ fibrillogenesis was poorly understood. Numerous 
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laboratories investigated the mechanism governing Aβ fibrillogenesis by utilizing 
synthetic peptides. However, investigating the kinetics of Aβ fibril formation proved to 
be a challenging quest due to limitations on available techniques. FTIR spectroscopy, 
CD, turbidity, thioflavin-T binding or microscopy could not provide detailed information 
on fibril size, nor was it appropriate for real time analysis. Moreover, these techniques are 
of limited use in clarifying the structures of fibrillogenesis intermediates (Kirschner, 
Abraham et al. 1986; Fraser, Nguyen et al. 1991; Hilbich, Kisters-Woike et al. 1991). The 
in vitro finding that Aβ fibrillogenesis follows a nucleation-dependent polymerization 
mechanism (as illustrated in Figure 1.4a) was first verified in 1986 when Teplow’s group 
extensively studied the nucleation and growth of Aβ(1-40) fibrils using quasielastic light 
scattering spectroscopy (QLS) along with size exclusion chromatography (SEC) and 
electron microscopy (EM) (Lomakin, Chung et al. 1996). QLS is a useful technique in 
monitoring the sizes of protein polymers in solution. The combination of QLS, SEC, and 
microscopy allows a direct and rapid estimation of the Aβ oligomerization state (Walsh, 
Lomakin et al. 1997).  
The Aβ kinetic process is dependent on two parameters, namely the nucleation 
rate and the rapid elongation or growth rate (Figure 1.4b, (Nilsson 2004)). Nucleation is 
considered to be an initial rate-limiting step characterized by a lag period in which Aβ 
monomers self-associate to form micelles of Aβ from which fibrils materialize and 
elongate (Serpell 2000; Carrotta, Barthes et al. 2007). The lag period of initial association 
of monomers to form a nucleus is an entropically unfavorable process (Nilsson 2004). 
However, once nucleus is formed, the aggregation proceeds rapidly to form fibrils. The 
lag phase can be overcome experimentally by several ways such as seeding and other  
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Figure 1.4. Mechanism of Aβ fibril- formation  (a) Process of Aβ fibril-formation from 
monomers follows a nucleation-dependent polymerization mechanism  (illustration from Walsh, 
Lomakin et al. 1997). (b) The nucleation polymerization model of aggregation follows two 
processes: nucleation, which is a slow process, and elongation which is rapid. The lag phase in 
nucleation process can be eliminated using various parameters such as variations in pH, 
temperature, solvent or buffer system,  peptide concentration, or peptide sequence among others 
(illustration from Nilsson 2004). 
 
 
 
 
(a) 
(b) 
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biophysical processes (briefly discussed in section 1.4.3)  Several laboratories have 
shown that Aβ fibril polymerization proceeds with the formation of dimers, tetramers, 
and finally oligomers (Tjernberg, Callaway et al. 1999). Moreover, further structural and 
kinetic characterization of Aβ fibrillogenesis utilizing X-ray fiber diffraction, light 
scattering, SEC and microscopy methods revealed that a time-dependent decrease in 
dimer levels was paralleled by an increase of transient prefibrillar intermediate in the 
fibril assembly, termed protofibrils (Harper, Wong et al. 1997; Walsh, Lomakin et al. 
1997; Harper, Wong et al. 1999; Walsh, Hartley et al. 1999; Serpell 2000). Protofibrils 
are small elongated oligomers with beaded appearance observed early on in the Aβ fibril 
formation process, are about 2.7 to 4.2 nm in diameter, and measure <200 nm in length 
which disappeared immediately with longer incubation time and were replaced by rigid, 
amyloid-type full-length fibrils (Harper, Wong et al. 1997; Kowalewski and Holtzman 
1999; Walsh, Hartley et al. 1999; Dumery, Bourdel et al. 2001; Kayed, Head et al. 2003). 
Harper et al (1997) investigated Aβ(1-40) protofibril formation by AFM and reported the 
appearance of small elongated Aβ oligomers with average height of 4.3 ± 0.5 nm and 
lengths that range from 20-70 nm, characteristic of protofibrils (Harper, Wong et al. 
1997). Using QLS, Walsh et al reported a hydrodynamic radius RH of 27.8 ± 1.8 nm for 
the initially formed protofibrils, and steadily increased to a maximal value of 80.6 ± 14.4 
nm (Walsh, Hartley et al. 1999). Other evidences have demonstrated that protofibril 
formation was observed at the early stages of both Aβ(1-40)and Aβ(1-42) fibrillogenesis 
although they have differences in the diameter (~4.2 nm for Aβ (1-42) and ~2.2 nm for 
Aβ(1-40) ) that may be attributed to the extra two residues of Aβ(1-42) (Harper, Wong et 
al. 1997). Radiochemical and immunological assays revealed that other short-lived 
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intermediates are being produced prior to protofibril formation, however, it is the dimer 
and protofibrils that accumulate during fibrillogenesis substantiating the main idea that 
protofibrils act as centers of growth of mature fibers (Walsh, Lomakin et al. 1997). AFM 
analysis demonstrated that protofibril height is 40% that of fibrils (Harper, Wong et al. 
1997; Harper, Wong et al. 1999). Several evidences also showed that protofibrils were in 
equilibrium with lower molecular weight (LMW) Aβ in the course of Aβ fibril formation. 
Further characterizations revealed that protofibrils are not easily sedimented, are too 
small to produce turbidity, and have significant β-sheet content, as shown by binding to 
Congo red and thioflavin T, as well as CD data (Harper, Wong et al. 1997; Walsh, 
Hartley et al. 1999).  
Active research on the mechanism of Aβ fibrillogenesis resulted in several 
proposed models that may further clarify the transition from protofibril to fibril 
formation. One possible mechanism introduced is end-to-end association of protofibrils. 
However, this model is unlikely due to kinetic barriers that may be encountered with 
regards to proper alignment of protofibril ends. Another possible mechanism is “lateral 
association” in which protofibrils combine laterally followed by addition of smaller Aβ 
species (ie. monomers and dimers) to the end. Lateral association of protofibrils followed 
by end-to-end annealing is another possible alternative explanation for Aβ fibril 
formation (Burdick, Soreghan et al. 1992; Harper, Wong et al. 1997; Walsh, Lomakin et 
al. 1997; Walsh, Hartley et al. 1999; Nichols, Moss et al. 2002).   
The investigation of Aβ fibrillogenesis proved to be a very challenging endeavor. 
Numerous investigators reported other structures preceding fibril formation including 
Aβ-derived diffusible ligands (ADDLs), Aβ*56, “globulomers” and “Aβ oligomers” 
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(Roychaudhuri, Yang et al. 2009). These fibrillar intermediates differ in morphology and 
size, but it is still a challenge to distinguish one from the other. AFM analysis showed 
that ADDLs are small “globules” of diffusible Aβ oligomers that measures 4.8 to 5.7 nm. 
Further characterization of ADDLs by western blot analysis and SDS revealed a 
molecular weight that ranges between 17 and 42 kDa, with the predominant species at 27 
kDa (Lambert, Barlow et al. 1998). Aβ*56, which has a molecular weight of 56 kDa 
characteristic of dodecameric species and morphology of prostate ellipsoid, was isolated 
and identified from brains of Tg2576 mice (Lesne, Koh et al. 2006). AFM analysis of the 
isolated Aβ*56 measured ~1 nm in height (Cheng, Scearce-Levie et al. 2007). On the 
other hand, “globulomers”, so called due to the globular oligomeric structure, do not form 
fibrils despite their ability to form β-sheet structure (Gellermann, Byrnes et al. 2008). Aβ 
oligomers that were produced in vitro were found to be composed of 15 – 20 monomers,  
with approximate MW of ~90,000 characteristic of an octadodecamer (Kayed, Head et al. 
2003). Taken together, these intermediate species were termed “soluble oligomers” 
(Deshpande, Mina et al. 2006). This general term applies to all forms of Aβ that do not 
pellet down after high speed centrifugation (typically >100,00g for more than 1h) (Irvine, 
El-Agnaf et al. 2008). 
It is apparent that the extensive efforts of various laboratories to study and 
elucidate the mechanism of Aβ fibrillogenesis unexpectedly revealed a wide range of 
fibrillar and oligomeric intermediates that may have a contribution to development of 
AD. Biochemical and biophysical methods such as size measurement, however, could not 
sufficiently provide the required sensitivity to distinguish one aggregation state to 
another. Recent advances in the study of Aβ polymerization have included the use of 
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conformation-specific antibodies that recognize generic structural features for providing 
more detailed and sensitive information about the identity of aggregated species 
(O'Nuallain and Wetzel 2002; Kayed, Head et al. 2003; Glabe 2004). The continuing 
progress in the research of Aβ polymerization process, and the availability of numerous 
tools for studying Aβ aggregation, are instrumental for elucidating the pathogenesis of 
AD and in designing strategies for therapeutic intervention. 
 
1.2.5 Correlation between Aβ assembly and AD 
 
According to the Aβ cascade hypothesis, the overproduction of Aβ or the 
increased proportion of the Aβ42/Aβ40 ratio is the basic pathophysiological process that 
causes early-onset AD. Over the years, numerous in vitro and in vivo studies have 
demonstrated that the fibrillar form of Aβ is toxic to the neurons (Table 1.1 (Mattson 
1997)). Several investigators, for instance, Yankner et al (Lorenzo and Yankner 1994) 
studied the neurotoxicity of different Aβ species by creating nonamyloidogenic 
amorphous Aβ aggregates and the amyloidogenic Aβ fibrils and comparing their 
neurotoxic effects to primary rat hippocampal cultures. The prepared peptides were 
characterized by microscopy and Congo red staining technique. For this study, 20 μM of 
Aβ was applied to the hippocampal cultures and the biological effects were determined 
by immunohistochemical process. Their results showed that the fibrillar form caused 
significant neuronal cell loss and synapse loss while the nonfibrillar form was not toxic. 
The neurotoxic effects of fibrillar Aβ to neurons were also demonstrated by other 
laboratories as well (Kowall, Beal et al. 1991; Pike, Burdick et al. 1993; Geula, Wu et al. 
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Table 1.1. Cytotoxic actions of amyloid-β peptide (adapted from (Mattson 1997)) 
Cell Type Toxic Action 
Hippocampal neurons Cell death, sensitivity to excitotoxicity 
Cortical neurons Cell death, sensitivity to excitotoxicity, 
sensitivity to energy depletion, impaired 
muscarinic signaling 
Neocortical neurons Cell death 
Neuroblastoma cells Cell death 
PC12 cells Impaired mitochondrial function 
Synaptosomes Impaired glutamate transport, impaired 
mitochondrial function 
Astrocytes Reactive phenotype, glutamate transport 
impairment 
Microglia Cell activation/injury 
Smooth muscle Damage and death 
Vascular endothelial 
Impaired glucose transport, loss of barrier 
function, apoptosis influx 
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 1998). However, upon analyzing the post-mortem brains of the diseased patients, there is 
insubstantial correlation between dementia and the density of fibrillar amyloid (Walsh, 
Klyubin et al. 2002b; Walsh and Selkoe 2007; Irvine, El-Agnaf et al. 2008). This 
observation eventually became a flaw of the amyloid-β cascade hypothesis.  
In contrast, for the past decade, evidences of the significant connection between 
soluble Aβ levels and the extent of synaptic loss and cognitive impairment have 
continuously emerged (Lambert, Barlow et al. 1998; Lansbury 1999; Lue, Kuo et al. 
1999; Walsh and Selkoe 2007). The use of synthetic Aβ peptides, cell systems with over-
expressed APP, APP transgenic mouse models and human CSF and postmortem brain 
contributed to the conclusion that soluble Aβ induces neurotoxicity rather than fibrillar 
Aβ (Kirkitadze, Bitan et al. 2002; Irvine, El-Agnaf et al. 2008).  Krafft and coworkers 
(Roher, Chaney et al. 1996) isolated Aβ from the post-mortem brain of AD patients, 
characterized the peptides using SEC, mass spectrometry (MS), and microscopy 
techniques, and applied the peptides to cultures of rat hippocampal neuron glia cells. 
Their study shows that dimers caused neuronal killing in the presence of microglia.   
Similarly, Teplow’s group demonstrated using MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) assay that protofibrils perturb the normal 
metabolism of cultured rat cortical neurons, which may be an early indicator of neuronal 
dysfunction and cell death (Walsh, Hartley et al. 1999). 
Utilizing Tg(APPSwe)2576Kahs mice (Tg2576), a well-characterized APP 
transgenic mouse model that expresses APP mutation that is linked to AD, Lesne and 
colleagues investigated the cause of memory decline in the absence of neurodegeneration 
(Lesne, Koh et al. 2006). Using the performance on the Morris-water maze as a measure 
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of spatial memory, they showed that mice started to develop memory deficits during the 
middle age (6-14 months). When they analyzed the Aβ species in the forebrain extracts of 
these mice, they found that the nonameric and dodecameric Aβ species correlated with 
the impairment of spatial memory. 
Despite the emerging evidences implying the toxicity of soluble oligomers and 
their ability to cause neuronal injury,  it must be emphasized that the large insoluble Aβ 
fibrils have been observed in the vicinity of the plaques and are also likely to be 
intimately surrounded by a number of soluble oligomers. Taken together, the conclusion 
that the large insoluble deposits, or the small oligomeric structures are the sole neurotoxic 
entity is not yet established. Rather, it may be possible that there is a continuous 
exchange between the two forms and both species are detrimental.  
 
1.3 AD and inflammation 
 
 Closer analysis of the senile plaques observed in AD revealed the presence of 
several cells that include astrocytes and activated microglia (El Khoury, Moore et al. 
2003). Astrocytes are the largest population of cells in the central nervous system (CNS). 
These cells function as major contributors to the structure and preservation of the blood-
brain barrier (BBB). They also help in maintaining homeostasis of the extracellular 
environment (Moore and O'Banion 2002). In the presence of inflammatory stimulus, 
astrocytes respond by expressing class I and II major histocompatibility molecules 
(MHC-I and MHC-II, respectively). However, astrocytes are deficient in costimulatory 
molecules. This deficiency inhibits them from presenting the antigen to naïve T-cells 
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although they can present antigens to primed memory T cells (Halliday, Robinson et al. 
2000).  
 Microglial cells are the resident immune cells of the CNS  with properties and 
staining characteristics similar to macrophages (Ulvestad, Williams et al. 1994; Halliday, 
Robinson et al. 2000). The morphology of the microglial cells was first described in 1932 
by Rio-Hortega in silver carbonate-stained brain preparations at the light microscope 
level (Rio-Hortega 1932; Lee, Nagai et al. 2002). Under normal physiological conditions 
and in the normal adult brain, the microglia are found as “resting” microglia, and adopt a 
characterized by a small cell body with fine and ramified processes and low expression of 
surface antigens (Garden and Moller 2006). The role of “resting” microglia is for immune 
surveillance and host defense (Liu and Hong 2003). Microglial cells are considered the 
first line of host defense against pathogens. However, when there is an injury or infection 
in the CNS, the “resting” microglia becomes activated, bringing about a change in 
morphology from ramified morphology to a more spherical cell morphology and more 
elongated or extended processes (Fischer and Reichmann 2001). Moreover, similar to 
activated astrocytes, activated microglia up-regulate a variety of cell-surface receptors, 
including MHC-II, proinflammatory cytokines and chemokines which include tumor 
necrosis factor alpha (TNFα), free radicals (NO), reactive oxygen species (ROS) and 
complement proteins (Moore and O'Banion 2002; Liu and Hong 2003).  
  Numerous studies of AD have demonstrated that microglia often cluster at sites of 
extracellular deposits of Aβ (Masumura, Hata et al. 2000). The first animal model 
evidence linking Aβ plaque formation with microglial activation was reported in 1998 
when Cole and co-workers utilized hybrid Tg2576(HuAPPsw) mice (Tg2576 with 
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Swedish familial K670N/M671L double mutation) in probing microglial response to Aβ 
formation (Frautschy, Yang et al. 1998). This transgenic mouse model progressively 
develops Aβ deposits that test positive in Congo red staining between 26 and 32 weeks of 
age. Swedish mutation also increases the total cerebral burden of Aβ than with the mutant 
APP (Buxbaum and Tagoe 2000). In the study, Cole et al. used Griffonia simplicifolia 
(GS) lectin labeling and phosphotyrosine staining to identify microglia. These methods 
were chosen due to the fact that GS lectin specifically labels microglia in the rodent brain 
(Kato, Kogure et al. 1995) and plaque-associated microglia express high levels of 
phosphotyrosine (Akiyama, Barger et al. 2000). The investigators’ results demonstrate 
that an increased density of enlarged microglia gathered in and around plaques that are 
present predominantly in the hippocampus and cerebral cortex of 10- to 16-month 
HuAPPsw mice. This finding is very similar to the microglial activation related to Aβ 
formation in the AD brain.  
  Similar transgenic mouse (Tg2576APPSW) model studies showed activation of the 
microglial cells in and around the fibrillary Aβ plaque perimeter (Apelt and Schliebs 
2001; Wegiel, Wang et al. 2001).  Moreover, several studies have demonstrated the 
microlia’s capacity to phagocytose and internally degrade Aβ (Frautschy, Cole et al. 
1992; Moore and O'Banion 2002). This phagocytic activity of microglia is considered to 
be an antigen-presenting ability of the microglial cells and this may be substantial in 
activation of the immune response. 
  Evidences have also emerged as to the contribution of Aβ in neurotoxicity and 
AD pathogenesis. Both in vivo and in vitro studies have shown that Aβ(1-42) induce 
neuronal apoptosis (Kowall, Beal et al. 1991; Loo, Copani et al. 1993; Pike, Burdick et 
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al. 1993; LaFerla, Tinkle et al. 1995; Masumura, Hata et al. 2000; Combs, Karlo et al. 
2001; Morishima, Gotoh et al. 2001) as manifested by changes in morphology and 
biochemistry of the neurons, such as membrane blebbing, compaction of nuclear 
chromatin and intrernucleosomal DNA fragmentation (Loo, Copani et al. 1993; LaFerla, 
Tinkle et al. 1995).   
  Perhaps the most studied effect of Aβ in neuroinflammatory process is as an 
inflammatory stimulus. It has been well documented that AD is characterized by a wide 
array of pro- and anti-inflammatory mediators. Analysis of microglia associated with 
senile plaques showed the presence of or a significant upregulation of inflammatory 
activity, such as production of cytokines and chemokines including interleukin (IL) -1β, 
IL-6, TNF-α, IL-8, transforming growth factor-β (TGF-β), and macrophage inflammatory 
protein-1α (MIP-1α), as compared to the age-matched, non-demented controls (Table 
1.2) (Akiyama, Barger et al. 2000; Halliday, Robinson et al. 2000; Dumery, Bourdel et al. 
2001; Perry, Newman et al. 2003). Likewise, several in vitro immunohistochemical 
studies have demonstrated the same findings of Aβ-induced microglial upregulation of 
cytokines and chemokines (Meda, Cassatella et al. 1995; Yates, Burgess et al. 2000; 
Apelt and Schliebs 2001; Floden and Combs 2006). Using an in vitro cellular model of 
human monocytes/macrophages, Klegeris et al. showed that Aβ peptide induced TNFα 
secretion on THP-1 cells (Klegeris, Walker et al. 1997). These accumulated data of an 
increased level of the proinflammatory products in the vicinity of senile plaques suggests 
that a chronic inflammatory process contributes to the progression of AD. Despite the 
numerous studies showing that several of these bioactive species promote 
neurodegenerative mechanisms, others exert beneficial neurotrophic effects (Halliday, 
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Robinson et al. 2000). 
  The role of TNFα in AD, for instance, is surprisingly controversial since it has 
both pro-apoptotic and anti-apoptotic effects. This proinflammatory cytokine, which is a 
powerful inflammatory mediator,  is reported to kill human cortical neurons (Good, 
Werner et al. 1996; Venters, Tang et al. 1999) and was found to be accountable for the 
neurotoxic activity of microglia such as an increased expression of inducible nitric oxide 
synthase (Combs, Karlo et al. 2001). Along with interferon gamma (IFNγ), TNFα is s a 
potent paracrine stimulator of other proinflammatory cytokines (Perry, Collins et al. 
2001). On the other hand, TNFα production has also been reported to have a 
neuroprotective role in neurons by inducing the expression of protective molecules 
including manganese superoxide dismutase (Akiyama, Barger et al. 2000).  
  There is strong evidence of increased levels of TNFα in the brain microvessels 
and cerebrospinal fluid of clinically diagnosed AD patients (Bruunsgaard, Andersen-
Ranberg et al. 1999; Tarkowski, Blennow et al. 1999; Tarkowski, Andreasen et al. 2003).  
For example, Blasko et al showed that TNFα, in combination of interferon (IFN)-γ,  
increases the production of Aβ and inhibits the production of soluble APP in human 
neuronal and nonneuronal cells (Blasko, Marx et al. 1999). These demonstrate the 
participation of proinflammatory factors in the exacerbation of AD pathology.  
  Thus, vast data now have convincingly demonstrated that extracellular deposition 
of Aβ in the AD brains triggers inflammation. How Aβ stimulates microglia at a 
molecular level is still unclear. Several studies have shown that Aβ induces glial 
activation through nuclear factor- κB (NF-κB) (Akama, Albanese et al. 1998; Bales, Du 
et al. 2000; Combs, Karlo et al. 2001). Moreover, several laboratories suggested the 
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Table 1.2. Microglial antigens and inflammatory mediators elevated in Alzheimer’s 
disease (reproduced from (Perry, Newman et al. 2003)) 
Surface/membrane receptors MHC class I, MHC class II 
Leukocyte common antigen,  
CD11a 
Complement receptor 3 
Complement receptor 4 
Vitronecting receptor 
Fc-γ receptor  
CSF1 receptor 
Macrosialin (CD68) 
 
Complement and related proteins 
 
C1q, C3, C5, C6, C7, C8, C9 
C3b, C4b and C5b opsonins 
C5b9 membrane attack complex 
C4 binding proteins 
Clusterin (apolipoprotein J) 
 
Cytokines and Chemokines (and 
receptors) 
 
IL1β 
IL6 (IL6R, gp130) 
TNFα 
TGFβ1, 2 (TGFβRI, TGFβRII) 
IL8 (CXCR2) 
MIP1α (CCR3, CCR5) 
MIP1β (CCR3, CCR5) 
MCP1 (CCR3, CCR5) 
 
Effector enzymes 
 
Cyclooxygenase 2 
Inducible nitric oxide synthase 
 
Acute phase proteins 
 
Plasminogen activator inhibitor-1 
α1-Antichymotrypsin 
Tissue plasminogen activator 
Urokinase plasminogen activator 
Protease nexin-1 
α2- Macroglobulin 
Serum amyloid protein 
C-reactive protein 
Thrombin 
Apolipoprotein E 
α2-Antiplasmin 
CD, cluster differentiation; CSF, colony stimulating factor; IL, interleukin, MCP, monocyte 
chemoattractant; MHC, major histocompatibility complex; MIP, macrophage inflammatory 
protein; TGF, transforming growth factor; TNF, tumor necrosis factor 
 
 
  32
 involvement of receptors in Aβ-induced microglial activation. For instance, El-Khoury et 
al. (El Khoury, Hickman et al. 1996) reported that the scavenger receptor on the surface 
of microglia binds to Aβ fibrils leading to cell adhesion and activation. Furthermore, 
other investigators suggested that Aβ-induced microglial activation is due to Aβ binding 
to the receptor for advanced glycation end products (RAGE) (Yan, Chen et al. 1996; 
Walsh, Lomakin et al. 1997). Using myeloid cells (e.g., THP-1 monocytes) and 
microglia, Bamberger et al. reported the involvement of a receptor complex (B-class 
scavenger receptor CD36, integrin associated protein/CD47 and the α6β1-integrin) for 
microglial activation and proinflammatory response by fibrillar Aβ (Bamberger, Harris et 
al. 2003). Recently, Fassbender’s group showed that fibrillar Aβ(1-42) interacts with LPS 
accessory receptor CD14 and triggers the release of proinflammatory products in primary 
murine microglial cells and human peripheral blood mononuclear (PBM) cells 
(Fassbender, Walter et al. 2004). This involvement of CD14 in Aβ-induced microglial 
activation now presents a possible connection between innate immunity and AD 
pathology. 
 
1.4 Toll-like Receptors and Innate Immunity 
 
  “Immunity” refers to the ability of the host to protect itself from microbes that 
would otherwise destroy it (Hoebe, Janssen et al. 2004). Immunity can be broadly 
classified into two inducible systems: the innate immunity (‘natural immunity’) and 
adaptive immunity (‘acquired immunity’) (Kielian 2006). During infection, these two 
systems are activated sequentially to fight off and eliminate the microbe. Innate immunity 
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is the first line of host defense towards these invading microbes while adaptive immunity 
is activated later, usually about 4-7 days after infection (Albiger, Dahlberg et al. 2007). 
The adaptive immune response is mediated by clonally distributed B and T lymphocytes 
and is characterized by specificity and memory (Akira, Uematsu et al. 2006). Microbial 
recognition involves the production of random and highly diverse antigen T- and B- cell 
receptors, followed by clonal selection and amplification of these receptors with relevant 
specificities. This mechanism requires augmentation and differentiation of the specific 
clones into effector cells before they can contribute to host defense. The whole process 
takes, as mentioned above, about 4-7 days thus making adaptive immune response a 
delayed response   (Akira, Takeda et al. 2001; Janssens and Beyaert 2003).   
  Innate immune response, on the other hand, is responsible for early detection of 
invading pathogens. It is largely mediated by white blood cells (neutrophils and 
macrophages), natural killer cells, dendritic cells, as well as perivascular macrophages 
and microglia in CNS  (Aderem and Ulevitch 2000; Kielian 2006). Originally thought of 
as nonspecific, later investigations showed that innate immune response can discriminate 
self and a variety of potential pathogens. Cells of the innate immunity effectively 
recognize the antigens by predetermined sets of germline-encoded pattern recognition 
receptors (PRRs) (Janssens and Beyaert 2003; Lee and Kim 2007). These PRRs are 
involved in opsonization, activation of complement and coagulation cascades as well as 
of proinflammatory signaling cascades, phagocytosis and apoptosis (Medzhitov 2001).  
  Because of limited receptor expression, the cells of the innate immune system 
recognize the antigen by virtue of highly conserved structures that are expressed on these 
invading microorganisms. These specific, highly conserved motifs are termed pathogen-
  34
associated molecular patterns (PAMPs) (Aderem and Ulevitch 2000; Kielian 2006; Lee 
and Kim 2007). PAMPs are produced only by microbes and not by host cells and do not 
vary between microorganisms of the same class. Moreover, they are vital for microbial 
survival. These features make them the perfect target for innate immune recognition 
(Medzhitov 2001). PAMPs recognition by PRRs results in activation of both extracellular 
(such as complement pathways) and intracellular signaling cascades that eventually 
culminate in the production of inflammatory response (Lee and Kim 2007).  
  The innate immune system uses PRRs that are located in three different 
compartments: those that are secreted into the blood stream and tissue fluids, expressed 
on the cell surface, or those that are expressed in intracellular compartments (Janssens 
and Beyaert 2003). PRRs in body fluids functions include PAMPs opsonization, 
activation of complement pathways and transfer of PAMPs to other PRRs. PRRs on the 
cell surface presents PAMPs to other PRRs, promotes phagocytosis, and initiates major 
signaling pathways. The cytoplasmic PRRs, on the other hand, are involved in 
antibacterial immune response and antiviral defense (Lee and Kim 2007). One of the 
most important and best characterized pattern recognition receptor families on the cell 
surface are the Toll-like receptors.  
 
1.4.1 Toll-like receptors (TLR)  
 
  Toll like receptors (TLRs) are products of evolutionary process. Analogous 
receptors are found in plants, insects, worms (Caenorhabditis elegans) and vertebrates 
(Albiger, Dahlberg et al. 2007). The founding member of the Toll family, termed Toll, 
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was identified in 1996 in the fruit fly Drosophila melanogaster (Parker, Prince et al. 
2007). Drosophila Toll was initially reported to be responsible for controlling 
dorsoventral patterning during the fruitfly development (Medzhitov 2001; Kielian 2006; 
Glezer, Simard et al. 2007). Later, Lemaitre et al. (Lemaitre, Nicolas et al. 1996) reported 
that Drosophila Toll was also involved in antifungal immunity in adult fruit flies.  In this 
study, they utilized Toll-mutant Drosophila and found that these species rapidly succumb 
to fungal infection due to failure to induce Drosomycin, an antifungal peptide. When the 
Drosophila Toll was sequenced, Gay and Keith (Gay and Keith 1991) realized that their 
intracellular domains showed striking similarity  with the intracellular signaling domain 
of the mammalian interleukin-1 (IL-1) receptor. This discovery prompted investigators to 
search and identify mammalian Toll-like homologues. 
  TLRs are type I transmembrane proteins that are composed of a highly variable 
ectodomain of leucine-rich repeats (LRRs) and a highly conserved intracellular or 
cytoplasmic domain that is homologous to the interleukin-1 receptor (IL-1R) thus called 
Toll/IL-1 receptor (TIR) domain (Miggin and O'Neill 2006; Trinchieri and Sher 2007). 
LRR domains consist of 19-25 tandem repeats, each repeat contains 24-29 amino acids 
and is involved directly or through accessory molecules in ligand binding (Albiger, 
Dahlberg et al. 2007; Trinchieri and Sher 2007). TIR domain, on the other hand, interacts 
with TIR-domain-containing adaptor molecules for signal transduction (Janssens and 
Beyaert 2003). To date, 13 mammalian TLRs have been identified (10 human (TLR1-10) 
and 12 murine (TLR1-9 and TLR11-13)) (Kielian 2006; Konat, Kielian et al. 2006; 
Albiger, Dahlberg et al. 2007; Parker, Prince et al. 2007), and at least one agonist has 
been identified for each TLR, with the exception of TLR10 (Kopp and Medzhitov 2003; 
  36
Konat, Kielian et al. 2006). The agonists that are being recognized by TLRs, some of 
which are listed in Table 1.3, include microbial components in bacteria, fungi, parasites 
and viruses, including lipid-based cell wall components, microbial protein components 
and nucleic acids.  
  TLRs are expressed in several immune cells including human monocytes and 
macrophages, microglia, astrocytes, oligodendrocytes, dendritic cells (DC), B-cell, 
specific types of T-cells, as well as nonimmune cells such as fibroblasts and epithelial 
cells (Andreakos, Foxwell et al. 2004; Akira, Uematsu et al. 2006; Konat, Kielian et al. 
2006). Furthermore, expression of TLRs may be extracellular or intracellular. TLRs 1, 2, 
4, 5 and 6 are expressed on the cell surface while TLR 3, 7, 8 and 9 are almost 
exclusively found in intracellular compartments such as endosomes. TLRs that are 
intracellularly expressed have ligands that are mainly nucleic acids, and these ligands 
need to be internalized to the endosome before signaling is possible (Kielian 2006; 
Parker, Prince et al. 2007). 
  Figure 1.5 ( adapted from (Konat, Kielian et al. 2006)) illustrates the general 
signaling pathway by TLRs. Upon PAMPs recognition, TLR activation results in 
initiation of the downstream signaling pathway through recruitment and activation of a 
TIR-domain containing adaptor molecule, myeloid differentiation factor 88 (MyD88). 
Activation of MyD88 leads to further activation of other adaptor molecules such as 
serine/threonine kinase IL-1R-associated kinase (IRAK), which is associated with 
MyD88, as well as TNF-receptor associated factor 6 (TRAF6). This downstream 
activation cascade eventually leads to the activation of nuclear factor (NF)-κB family of  
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Table 1.3 Human TLRs and ligands (adapted from (Akashi-Takamura and Miyake 
2006; Albiger, Dahlberg et al. 2007)) 
TLR Major Ligands Major Ligands and species 
TLR1/TLR2 Triacyl lipopeptides Bacteria and mycobacteria 
TLR2 LTA 
 
Atypical LPS 
 
Porins 
 
Lipoarabinomannan 
Lipopeptides (Pam3CSK4, 
MALP2) 
Peptidoglycan 
Gram-positive bacteria, i.e. Staphylococcus 
aureus, Streptococcus pneumoniae, etc. 
Gram-negative bacteria, i.e. Phorphyromonas 
gingivalis 
Gram-negative bacteria, i.e. Neisseria sp., 
Shigella sp., Haemophilus influenzae 
Mycobacteria 
 
 
Gram-positive bacteria 
TLR3 dsRNA Virus 
TLR4 LPS 
Fusion protein 
EDA domain fibronectin 
HSP60 
Gram-negative bacteria 
RSV 
(endogenous) 
(endogenous) 
TLR5 Flagellin Flagellated Gram-positive and Gram-negative 
bacteria 
TLR6/TLR2 Diacylated lipopeptides 
Zymosan 
LTA 
Mycoplasma 
Yeast 
Group B streptococci 
TLR7 ssRNA Virus 
TLR8 ssRNA Virus 
TLR9 Unmethylated CpGDNA 
Herpes virus DNA 
Bacteria 
Virus 
TLR10 Not determined  
TLR11 Unknown Uropathogenic E. coli 
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Figure 1.5. The Toll-like receptor signaling pathway. TLR 
activation by PAMPs recognition results in the activation of 
the downstream signaling pathway that culminates in the 
production of proinflammatory cytokines and chemokines, as 
well as IFNβ. The initiation of downstream signaling begins 
by activation and recruitment of adaptor molecules such as 
MyD88 (as shown). TLR signaling pathway also utilizes a 
MyD88-independent pathway, wherein TIRAP, TRIF and 
TRAM adaptor molecules are recruited and activated (not 
shown).( illustration from Konat, Kielian et al. 2006)  
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transcription factors, as well as initiation of distinct parallel signaling pathways leading to 
mitogen-activated protein (MAP) kinase. Initiation of these pathways subsequently result 
in transcription of a myriad of pro- and anti-inflammatory cytokines, chemokines and 
costimulatory molecules, such as TNF-α, IL-6, IL-1β and IL-12 (Kielian 2006; Konat, 
Kielian et al. 2006; Albiger, Dahlberg et al. 2007; Guo and Schluesener 2007; Parker, 
Prince et al. 2007). 
  TLR also utilizes other adaptor proteins for downstream signaling through a 
MyD88- independent pathway. This pathway starts with the TLR recruitment of adaptor 
proteins such as Toll-IR-1 receptor (TIR)-associated protein (TIRAP, also known as 
MAL), Toll-associated activator of IFN (TRIF) and Toll receptor-associated molecule 
(TRAM), which are crucial for the expression of interferon (IFN)-inducible genes (Akira, 
Uematsu et al. 2006; Kielian 2006; Konat, Kielian et al. 2006; Miggin and O'Neill 2006).  
  The study of human TLRs has progressed in the last 5 years (Kielian 2006), and 
investigations on TLR expression are rapidly expanding. The following discussion will 
focus on the most common and well defined TLRs, TLR2 and TLR4, as well as TLR 
accessory proteins. 
 
1.4.1.1 TLR4  
 
  TLR4 is perhaps the most extensively studied PRR. Furthermore, human TLR4 
was the first characterized mammalian Toll (Medzhitov, Preston-Hurlburt et al. 1997). 
Like other TLRs, TLR4 is expressed in various cell types, predominantly in immune cells 
such as macrophages and DCs (Medzhitov 2001). It recognizes a variety of ligands, like 
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mannan (yeast) and host heat shock proteins and fibrinogen (virus) (Albiger, Dahlberg et 
al. 2007); however, TLR4 is mostly known to recognize gram negative bacterial cell wall 
component lipopolysaccharide (LPS) (Hoshino, Takeuchi et al. 1999). Hoshino et al  and 
several other investigators demonstrated that TLR4 mediates responses to LPS using 
several mouse models that are TLR4-gene deficient, or LPS hyporesponsive mouse 
strains  (Poltorak, He et al. 1998; Hoshino, Takeuchi et al. 1999; Qureshi, Lariviere et al. 
1999). LPS, a major constituent of the outer membrane of the Gram-negative bacteria, 
consists of three regions (Figure 1.6 (Miller, Ernst et al. 2005)): the O-polysaccharide 
chain, the core saccharide and the lipid A (Huber, Kalis et al. 2006). The O-specific chain 
consists of a polymer of oligosaccharides with a repeating unit of one to eight glycosyl 
residues. Core saccharide (or core region), on the other hand, is made up of 
heterooligosaccharide that is subdivided into inner and outer core (Rietschel, Kirikae et 
al. 1994). Lipid A is composed of a diglucosamine backbone containing ester-linked and 
amide-linked long-chain fatty acids (Aderem and Ulevitch 2000) and functions as a 
hydrophobic anchor of LPS on the major gram-negative outer membranes (Dixon and 
Darveau 2005). It was already postulated since the 1950s that the lipid A is the toxic 
component of LPS. But it was not until the late 1980s when the chemical structure of 
lipid A was elucidated and chemically synthesized, and the biological activity of 
synthetic lipid A was compared with bacterial lipid A and LPS that lipid A was shown to 
be, in fact, the bioactive component of LPS (Loppnow, Brade et al. 1989; Rietschel, 
Kirikae et al. 1994)    
LPS is an amphiphilic molecule and it forms aggregates in solution (Jerala 2007). 
Numerous evidences have established LPS as a powerful proinflammatory activator of  
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Figure 1.6 Chemical structure of known TLR agonists. (A) Bacterial 
lipopolysaccharide (LPS). (B) synthetic triacylated bacterial lipoprotein 
tripalmitoyl cysteinyl seryl tetralysine (Pam3CSK4). (C) synthetic 
diacylated bacterial lipoprotein FSL-1. 
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mononuclear cells, and TLR4- dependent activation of macrophages and microglia by 
nanogram quantities of LPS results in the production of myriad cytokines such as TNF-α, 
IL-1, -6, -8, as well as nitric oxide (NO), and superoxide which are capable of inducing 
apoptotic cell death (Poltorak, He et al. 1998; Moore, Andersson et al. 2000). 
  The molecular pathway of TLR4 activation by LPS has been extensively studied 
and is depicted in Figure 1.7a and 1.7b (Aderem and Ulevitch 2000; Akashi-Takamura 
and Miyake 2006; Kielian 2006). LPS recognition by TLR4 starts with the lipid A moiety 
binding to a 58-60 kDa serum protein, human lipopolysaccharide-binding protein (LBP). 
LBP is a serum glycoprotein belonging to a family of lipid-binding proteins that includes 
bactericidal/permeability-increasing protein (BPI), phospholipid ester transfer protein and 
cholesterol ester transfer protein (Gutsmann, Muller et al. 2001). In normal serum, LBP is 
present at concentrations of ≈5 to 15 μg/ml (Kitchens, Wolfbauer et al. 1999).  
Investigations have shown that the function of LBP in LPS signaling is to convert 
oligomeric micelles of LPS to monomers, and to shuttle the monomeric LPS to CD14 
(Jerala 2007). Disaggregating the LPS increases the transfer and binding of LPS to CD14 
(Hailman, Lichenstein et al. 1994; Miller, Ernst et al. 2005). 
CD14, a 55-kDa high-affinity LPS receptor, can either be secreted in the serum 
(soluble or sCD14) or expressed as a glycophosphoinositol (GPI)-anchored protein 
(membrane or mCD14) on the surface of macrophages. Pugin et al reported the sCD14 
level in normal serum to be 2 to 3 μg/ml (Pugin, Schurer-Maly et al. 1993).  Several 
biochemical and genetic evidences showed that CD14 binds to LPS with dissociation 
constant (KD) between 30 and 74 nM (Miyake 2004) and facilitates its signaling, but it 
does not appear to be essential in direct LPS response (da Silva Correia, Soldau et al.  
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Figure 1.7. TLR2 and TLR4 signaling pathway. (a) TLR4 signaling starts with the 
binding of LPS, the most common TLR4 ligand, to LBP. LBP then transfers monomeric 
LPS to CD14. CD14 then presents LPS to TLR4:MD2. The trimeric complex 
LPS:TLR4:MD2 activates downstream TLR signaling leading to formation of 
proinflammatory products (Aderem and Ulevitch 2000). (b) Both TLR2 and TLR4 
utilize the adaptor molecule MyD88 for downstream signaling pathway. TLR2 forms a 
complex with either TLR1 or TLR6 for recognition of triacylated or diacylated 
lipopeptide, respectively (illustration from Kielian 2006).  
(a) 
(b) 
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2001). Although CD14-knockout mouse studies have shown that LPS responses are 
detectable without CD14, this TLR accessory protein is essential for the initiation of the 
TRAM-TRIF pathway by TLR4/MD2 (Jiang, Georgel et al. 2005). Moreover, the 
significance of CD14 in LPS signaling was evidenced  in vivo by an impaired TNFα 
response when CD14-deficient mice were challenged with LPS (Haziot, Ferrero et al. 
1996).  
  In vitro studies showed the LPS/CD14 complex utilizes another host-derived 
soluble adaptor molecule for the activation of downstream TLR signaling. This co-
receptor, termed MD-2, is a 25-30 kDa protein, lacks the transmembrane and intracellular 
region and is expressed on the cell surface in association with the ectodomain of TLR4 
(Akira, Takeda et al. 2001; Medzhitov 2001; Akashi-Takamura and Miyake 2006; 
Kielian 2006). LPS bound to CD14 is transferred to MD-2, which associates with the 
ectodomain of TLR4. Together, the MD-2/TLR4 oligomer binds LPS with nanomolar 
affinity and the trimeric complex LPS:MD-2:TLR4 induces LPS signaling, translocation 
of nuclear proteins and transcriptional activation of genes associated with the 
inflammatory processes (Viriyakosol, Tobias et al. 2001; Akira, Uematsu et al. 2006; 
Glezer, Simard et al. 2007). 
  TLR4 interaction with MD-2 is crucial for efficient responses to LPS. This was 
supported by experiments that demonstrated unresponsive phenotype of mice carrying 
knockout mutations in either TLR4 or MD-2 genes (Hoshino, Takeuchi et al. 1999; 
Shimazu, Akashi et al. 1999; Nagai, Akashi et al. 2002). Recent efforts to elucidate the 
MD-2:TLR4 binding to LPS showed that the TLR4 region Glu24-Lys47 is the site for MD-
2 binding. Moreover, Cys29 and Cys40 within this region are critical for interaction with 
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MD-2 and LPS signaling (Nishitani, Mitsuzawa et al. 2006). Furthermore, a model for 
LPS-induced TLR4:MD-2 dimer was constructed based on mutational analysis wherein 
the structure formed resembles the ‘m’ shaped dimers (Jin and Lee 2008). Crystal 
structures of human MD-2 and its complex with LPS lipid A suggested that MD-2 plays a 
principal role in endotoxin recognition (Ohto, Fukase et al. 2007). Several lines of 
evidence also showed that TLR4 and MD-2 are important in ligand-recognition 
specificity (Shimazu, Akashi et al. 1999; Miyake 2004; Prohinar, Re et al. 2007), thus, it 
is plausible that TLR4 and MD-2 work together for ligand recognition and signal 
transduction.  
 
1.4.1.2 TLR2, TLR1, TLR6 
 
Among all the TLRs that have been identified, TLR2 is considered the one with 
the broadest specificity when it pertains to PAMPs recognition. TLR2 has been shown to 
recognize a broad range of microbial products including peptidoglycan (PGN) from 
Gram-positive bacteria, bacterial lipoproteins (LP), mycobacterial cell-wall 
lipoarabinomannan, lipoteichoic acid (LTA), tripalmitoyl-S-glyceryl-cysteine (Pam3Cys), 
glycosylphosphatidylinositol lipid from Trypanosoma Cruzi, a phenol-soluble modulin 
produced by Staphylococcus epidermidis, zymoan from fungi and glycolipids from 
Treponema maltophilum (Janeway and Medzhitov 1999; Medzhitov 2001; Kielian 2006). 
Moreover, studies have also shown that TLR2 recognize atypical LPS, which is 
structurally different from bacterial LPS by virtue of the number of acyl chains in the 
lipid A component (Takeda, Kaisho et al. 2003), from Leptospira interogans (Medzhitov 
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2001) and Porphyromonas gingivitis (Hirschfeld, Weis et al. 2001). The wide spectrum 
of microbial components that TLR2 can recognize may be due, in part, to the ability of 
TLR2 to cooperate or complex with at least two other TLRs: TLR1 and TLR6. Therefore, 
TLR2 dimer formation with TLR1 or TLR6 may dictate specificity of ligand recognition 
(Ozinsky, Underhill et al. 2000; Takeuchi, Kawai et al. 2001; Akira, Uematsu et al. 
2006). For instance, TLR2/TLR1 heterodimers preferentially act as a receptor for 
triacylated lipopeptides whereas TLR2/TLR6 heterodimers are the receptors for 
diacylated lipopeptides (Figure 1.6) (Ozinsky, Underhill et al. 2000; Takeuchi, Kawai et 
al. 2001; Takeuchi, Sato et al. 2002; Dziarski 2003; Omueti, Beyer et al. 2005).  
TLR2 is expressed on monocytes, macrophages, microglia, dendritic cells, B cells 
and, to a lesser extent, on neutrophils and few other cells, whereas it has been shown that 
both TLR1 and TLR6 are expressed by microglia (Dziarski 2003; Kielian 2006). As 
presented in Figure 1.7b, TLR2 downstream signaling pathway begins with TLR2 
complex formation with either TLR1 or TLR6, afterwhich, the complex utilizes both the 
intracellular adaptor proteins MyD88 and TIRAP for subsequent induction of target 
genes such as TNFα and other cytokines and chemokines (Kielian 2006). 
Evidences also demonstrate the role of CD14 on TLR2 recognition of gram-
positive PAMPs, such as PGN and LTA. Schröder et al. used human embryonic kidney 
(HEK) cells and chinese hamster ovary (CHO) cells transfected with both TLR2 and 
CD14 to show that LTA of Streptococcus pneumoniae and Staphylococcus aureus utilize 
CD14 and TLR2 to activate immune cells (Schroder, Morath et al. 2003). Moreover, 
using a CD14 mutant with deletion of the part of possible N-terminal ligand binding 
pocket, and an anti-CD14 monoclonal antibody, Nakata’s group demonstrated that CD14 
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binds to triacylated lipopeptides and facilitates its recognition by TLR2/TLR1 complex 
(Nakata, Yasuda et al. 2006). Other investigations utilizing knockout mice and 
transfected cell lines also demonstrated the necessity of CD14 for TLR2/TLR1 or 
TLR2/TLR6 heterodimer recognition of PAMPs (Gupta, Kirkland et al. 1996; Henneke, 
Takeuchi et al. 2001; Dziarski 2003; Esen and Kielian 2005; Manukyan, Triantafilou et 
al. 2005). 
Earlier studies implicated TLR2, along with TLR4, as a receptor for LPS 
signaling (Kirschning, Wesche et al. 1998; Yang, Mark et al. 1998; Yang, Mark et al. 
1999). However, a closer examination revealed that the original discrepancy on the 
involvement of TLR2 in LPS activation was due to the contaminating lipoproteins, which 
are TLR2 ligands, in commercially available LPS preparations (Kielian 2006). In fact, 
when LPS was repurified and the contaminating lipoproteins were removed, the LPS was 
unable to signal via TLR2 (Hirschfeld, Ma et al. 2000). Thus, investigations of PAMPs 
recognition by TLRs require careful scrutiny to ascertain that the TLR agonists are not 
contaminated with other biologically active PAMPs. 
 
1.4.2 TLRs and Aβ: What is the connection? 
 
In 2003, Fassbender’s group published results demonstrating the role of CD14 in 
linking Aβ with the innate immunity (Fassbender, Walter et al. 2004). By surface 
plasmon resonance spectroscopy (SPR), immunoprecipitation and western blotting, they 
showed that CD14 binds fibrillar Aβ (1-42) with a dissociation constant (KD) of 1.1 ± 0.1 
x10-7 M. Moreover, CD14 binding to fibrillar Aβ42 was 20-fold stronger as compared to 
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CD14 and nonfibrillar Aβ (1-42) (KD [M] = 2.2 ± 0.7 x10-6). The huge difference in the 
KD values suggests that CD14 recognizes the β-sheet structure of the fibrillar Aβ(1-42). 
The group also tested the role of CD14 in fibrillar Aβ(1-42) – induced microglial 
activation using primary murine microglia from wildtype (WT) and CD14-deficient mice, 
treated the cells with fibrillar Aβ(1-42) and interferon (IFN)-γ, and analyzed the 
proinflammatory marker IL-6. Results showed that CD14-deficient microglia released 
significantly lower amounts of IL-6 in response to Aβ as compared to WT microglia. A 
significant reduction of proinflammatory products was also observed when human 
peripheral blood monocytes (PBM) induced with fibrillar Aβ was treated with anti-
human CD14 monoclonal antibody, 3C10. These data further strengthens the interaction 
between CD14 and fibrillar Aβ(1-42) in induction of proinflammatory products. The 
authors also showed overexpression of CD14 in APP transgenic mice, which signifies 
that CD14 significantly contributes to the inflammatory responses in AD.  
However, CD14 does not contain a cytoplasmic domain (Haziot, Chen et al. 1988; 
Muta and Takeshige 2001; Viriyakosol, Tobias et al. 2001; Kim, Lee et al. 2005) that 
could activate the downstream signaling that induces production of proinflammatory 
products (see Figure 4). As explained earlier, CD14 functions as a co-receptor for LPS 
(Wright, Ramos et al. 1990; da Silva Correia, Soldau et al. 2001; Medzhitov 2001), as 
well as for Gram-positive cell walls and their PGN component (Pugin, Schurer-Maly et 
al. 1993; Gupta, Kirkland et al. 1996; Henneke, Takeuchi et al. 2001; Muta and 
Takeshige 2001; Nakata, Yasuda et al. 2006). These PAMPs utilize TLR4 and TLR2 for 
intracellular signal transduction. Fassbender et al (Fassbender, Walter et al. 2004) 
proposed that the observed Aβ cellular activation may likely be transmitted by TLR4 
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based on the positive inflammatory response obtained from CHO cells which lack a 
functional TLR2. 
In this regard, the purpose of this research is to investigate the possible 
involvement of TLR(s) in Aβ(1-42) induction of the innate immune response. 
Specifically, this research aims to identify the TLR that functionally interacts with Aβ(1-
42). We also aim to investigate the possible involvement of other TLR accessory proteins 
and TLR complexes in Aβ(1-42) innate immune activation. The field of TLR research is 
still in its infancy; thus, the information that will be obtained from this research may 
contribute to increased understanding of how Aβ assemblies interact with TLR family 
members. Additionally, this investigation will contribute to further understanding the role 
of Aβ in AD-associated neurodegeneration, and possibly, open a therapeutically relevant 
perspective for TLRs and their recognition abilities for host-derived pathogens.
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2 GENERAL METHODS 
 
2.1 Cell Culture 
 
2.1.1 THP-1 monocytes 
 
2.1.1.1 THP-1 storage, growth and culture 
 
The cultured human peripheral blood THP-1 monocytes were obtained from 
ATCC (Manassas, VA, USA) and maintained in RPMI-1640 culture medium (HyClone, 
Logan, UT, USA) that contains 2 mmol/L L-glutamine, 25 mmol/L HEPES, 1.5 g/L 
sodium bicarbonate, 10% fetal bovine serum (FBS) (HyClone), 50 U/ml penicillin, 50 
μg/ml streptomycin (HyClone), and 50 μmol/L β-mercaptoethanol (Fisher, Pittsburg, PA) 
at 37oC in 5% CO2. For growth and maintenance, THP-1 monocytes were diluted three 
times a week, with a dilution of 1:1 twice during the week, and 3:10 dilution at the end of 
the week. For 1:1 dilution, half of the cells were removed from the flask and replaced 
with the same volume of fresh growth medium for propagation, ensuring that the cell 
concentration in the flask was maintained at 1 x106 cells/ml. For 3:10 dilution, 3 ml of 
THP-1 cells were removed from the culture flask and spun at 500 xg for 10 minutes. 
After centrifugation, supernatant was removed and cells were resuspended in 10 ml of 
growth medium. Cells were transferred to a new cell culture flask for propagation. Cells 
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were continuously subcultured for 3 weeks prior to experimentation. 
For maintaining a continuous supply of THP-1, THP-1 monocytes were 
cryopreserved. As soon as a small surplus of THP-1 cells becomes available for 
subculture, several ampules of cells were frozen. Cells were removed from the flask, 
centrifuged at 500 xg for 10 minutes and supernatant was removed without disturbing the 
pellet. The pellet was then resuspended to a final concentration of 5 x106 cells/ml in 
freezing medium (fresh growth medium containing 0.5% sterile dimethyl sulfoxide 
(DMSO)). The cell suspensions were dispensed into prelabeled ampules (1 ml cell 
suspension per ampule) and ampules were transferred to an ampule cooler (Nalge Nunc) 
containing isopropyl alcohol. The specific heat of the coolant in the base of the cooler 
insulates the container and gives a cooling rate of ~1oC/min in the ampules (Freshney, 
2000). The cooler was placed in a -70oC freezer overnight prior to transfer of ampules in 
liquid nitrogen. After overnight freezing at -70oC, ampules were rapidly transferred to a 
cryo-container and THP-1 cells were stored immersed in liquid nitrogen.  
Thawing THP-1 ampules needs to be rapid. THP-1 cells were thawed by 
immersing the lower half of the ampule in 37oC waterbath for 2-3 minutes (but not 
exceeding 3 minutes). The ampule containing thawed cells was then immersed in 70% 
ethanol before opening the container. Cells were pipetted out from the ampule and 
suspended in 9 ml of fresh THP-1 growth medium. Cell suspension was centrifuged, and 
reseeded in a new cell culture flask, as described previously. 
We have previously observed that the proinflammatory response of our THP-1 
monocytes to TLR agonists started to deteriorate when THP-1 cells have been 
subcultured continuously for greater than 2 months. To avoid this problem, we have 
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staggered our culture of THP-1 monocytes. We constantly maintained two culture flasks 
of THP-1 monocytes, in which one flask was cultured a month after the initial culture of 
the first THP-1 flask. Cells were constantly monitored for viability by stimulation with 
TLR agonists (section 2.3) and measuring TNFα production (section 2.7).  
 
2.1.1.2 THP-1 preparation for experimentation 
 
For cellular assays, THP-1 monocytes were removed from the culture flask and 
centrifuged at 500 x g for 10 minutes. After centrifugation, supernatant was removed 
without disturbing the pellet. The pellet was washed with THP-1 assay culture medium 
(THP-1 growth but with 2% FBS), and centrifuged as described above. Afterwhich, 
supernatant was removed and pellet was resuspended in assay medium. Cell 
concentration was determined by direct counting of the cells using a hemocytometer. 
THP-1 cells (with concentration maintained at 1x106 cells/ml) were added to individual 
wells of a 48-well sterile plate to a final volume of 0.3 ml, or 96-well cell culture plate to 
a final volume of 0.08 ml.  
THP-1 monocytes are derived from the blood of a patient with monocytic 
leukemia (Tsuchiya et al., 1980). The cells grow in suspension, have round morphology, 
and do not adhere to the plastic surfaces of the culture plates (Takashiba et al., 1999; 
Zhou et al., 2005). THP-1 can serve as a model of primary human microglia since they 
acquire a microglia-like morphology when treated with LPS (Yates et al., 2000).  
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2.1.2 Human Embryonic Kidney (HEK293) cells 
 
Null HEK293 (stably transfected with the pUNO-mcs vector), 293-hTLR2 cells 
(isolated clone of HEK293 cells stably transfected with human TLR2 gene), and 293-
hTLR2/CD14 (isolated clone of HEK293 cells stably transfected with human TLR2 and 
CD14 genes) were obtained from InvivoGen (San Diego, CA, USA). Null HEK293 and 
HEK 293-hTLR2 cells were maintained in  Dubelcco’s Modified Eagle’s Medium 
(DMEM) growth medium (HyClone) containing 4 mmol/L L-glutamine, 4.5 g/l glucose, 
10% FBS and supplemented with 10 μg/ml Blasticidin (InvivoGen) at 37oC in 5% CO2. 
HEK 293-hTLR2/CD14 cells were maintained in the same growth medium supplemented 
with 10 μg/ml Blasticidin and 50 μg/ml hygromycin (HygroGold™) (InvivoGen). Cells 
were subcultured in a T-75 cell culture flask every 4 days. The number of times the cells 
were subcultured is denoted by passage number. Subculture of HEK 293 cells is 
illustrated in Figure 2.1 and was done using the following procedure. Briefly, the growth 
medium in the flask was removed, and the cells were gently washed with sterile 
phosphate buffered saline (PBS) (Hyclone). After washing, the cells were treated with 2 
ml of 0.25% trypsin-EDTA for 5 minutes at 37oC followed by addition of 8 ml of 
corresponding growth medium. Cells were dispersed by repeated gentle pipetting over the 
surface bearing the monolayer. Cells were collected, placed in a 15 ml conical tube, 
centrifuged at 500 xg for 10 minutes, resuspended in appropriate fresh growth medium, 
diluted to the appropriate seeding concentration, and reseeded in a fresh flask (Freshney, 
2000). A surplus of HEK 293 cells were also cryopreserved in a similar manner as in 
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Figure 2.1 Schematic diagram of the subculture of HEK293 cells. Stages in the subculture and 
growth cycle of HEK293 cells following trypsinization (Freshney, 2000) 
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THP-1 monocytes (section 2.1.1.1), in which 1.0 ml aliquots of cells were kept in liquid 
nitrogen until needed for growth and culture. 
For cellular assays, Null HEK293, 293-hTLR2 and 293-hTLR2/CD14 cells were 
trypsinized, as described above, to dislodge the cells. Cell supernatant was centrifuged at 
500 xg for 10 minutes, and cells were resuspended in fresh growth medium. 0.3 ml or 0.2 
ml of cells was plated to individual wells of a 48-well or 96-well sterile culture plate, 
respectively. The cell concentration for a 48-well plate was maintained at 3.0 x105 
cells/ml, and 2.0 x105 for a 96-well culture plate. HEK293 cells were incubated and 
allowed to adhere for 4h at 37oC, 5% CO2. After incubation, growth medium was 
removed and HEK293 cells were resuspended in their respective assay medium (growth 
medium with reduced (2%) FBS) prior to treatment with effectors. 
We have optimized the conditions of HEK 293 growth to achieve the maximal IL-
8 concentration. We varied the length of adhesion of our HEK 293 cells to the cell culture 
plate prior to stimulation with effectors (section 2.3) and measured the IL-8 secretion 
after incubation (section 2.7). Results in Figure 2.2 showed the highest IL-8 production 
was achieved when HEK 293hTLR2 was allowed to adhere to the cell culture plate for 4 
hours prior to treatment with effectors. Thus, for all experiments with Null HEK 293, 
HEK 293hTLR2 and HEK293hTLR2/CD14 cells, cells were incubated for 4 hours prior 
to stimulation with effectors. Similarly, we tested if proinflammatory production by 
HEK293 cells is affected by the number of times the cells have been subcultured. Figure 
2.3 shows that the ability of HEK 293hTLR2 to produce IL-8 upon stimulation with 
fibrillar Aβ(1-42) aggregated for 216 hours at 4oC significantly decreased as the cells 
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Figure 2.2. Optimization of HEK 293 adhesion time prior to stimulation 
with Pam3CSK4. Null HEK293 (light gray bars) or HEK 293hTLR2 (dark 
gray bars) was prepared for experiment, as described. After resuspension in 
growth medium, cells were plated in a cell culture plate and allowed to 
adhere at 37oC, 5%CO2 for 0, 4, 24 or 72 hours prior to stimulation for IL-8 
production (in pg/ml). After the given times, growth medium was removed, 
resuspended in assay medium and cells treated with 1 ng/ml Pam3CSK4. 
After 24-hour post-stimulation, IL-8 was measured. HEK 293hTLR2/CD14 
cells were also tested and gave a trend similar to that of HEK 293hTLR2 
(data not shown).  
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aged. Therefore, for all experiments employing HEK293 cells, we used cells from either 
passage 15 or 16 to achieve maximal secretion of IL-8. 
 
2.2. Preparation of Aβ peptides 
 
Lyophilized powder of Aβ(1-42) and Aβ(1-40) peptides were purchased from 
rPeptide (Bogarth, GA, USA). The powder was dissolved in 100% hexafluoroisopropanol 
(HFIP) (Sigma, St. Louis, MO), and incubated at room temperature for 1 hour. This step 
is crucial to ensure disaggregation of any pre-formed aggregates. HFIP treatment also 
allows “normalization” of  the properties of different commercial preparations of Aβ 
(Wood et al., 1996; Zagorski et al., 1999).  After incubation, the peptides were aliquotted 
into sterile microcentrifuge tubes, dried in a vacuum centrifuge, and dried samples stored 
at -20oC. Before cell treatment, the lyophilized samples were resuspended to 100 μmol/L 
or 1 mmol/L in sterile water and incubated at 4oC. For studying the effect of temperature 
in Aβ(1-42) aggregation, prepared Aβ peptides were also stored at 25oC and 37oC. For 
cell treatment, cells were exposed to a final concentration of 15 μmol/L of Aβ(1-42) or 
Aβ(1-40).  
 
2.3 Activation of cell model systems 
 
THP-1 monocytes or HEK 293 cells were prepared for experiment as described 
above, and plated on a sterile 48-well or 96-well cell culture plate. To the wells, pure 
bacterial LPS (Escherichia coli 026.B6, Sigma), ultrapure bacterial LPS (Escherichia coli 
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Figure 2.3. Effect of HEK293 passage number on fibrillar Aβ(1-42) 
response. HEK293 hTLR2 cells were subcultured, as described. The number 
of times the cells have been subcultured is denoted by passage number. For 
each subculture, cells are prepared for experiment and stimulated with 15 μM 
of fibrillar Aβ(1-42) for 24 hours. After post-stimulation, secreted IL-8 was 
determined. This result represents 1 representative experiment of 3. Error 
bars represent n= 3 trials (1 experiment).  The same experiment was done in 
Null HEK293 cells and treatment with Aβ failed to stimulate Null HEK293 
cells for IL-8 production (data not shown)  
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 K12, InvivoGen), synthetic bacterial lipoprotein tripalmitoyl cysteinyl seryl tetralysine 
(Pam3CSK4, InvivoGen), synthetic Pam2CGDPKHPKSF (FSL-1, InvivoGen) (Figure 
1.6) or 15 μmol/L Aβ(1-42) or Aβ(1-40) were applied. For HEK 293 experiments, Aβ(1-
42) that was allowed to aggregate for 216 hours at 4oC was used. Cells were incubated at 
37oC, 5%CO2 at concentrations and incubation times stated in the experiments. After the 
indicated incubation time, cell supernatants were removed and centrifuged at 2500 xg for 
10 minutes (Microcentrifuge® 18 Centrifuge, Beckman-Coulter) to remove cells, and 
supernatants were collected and stored at -20oC prior to analysis of proinflammatory 
products (TNFα or IL-8). For concentration dependence experiment, the EC50 values 
were determined by fitting the concentration-dependence data for the agonists to a 
sigmoidal three-parameter equation (y = a/ [1 + e –([x-xo]/b) ) using SigmaPlot graphing 
program.  
 
2.4 Conversion of non-adherent THP-1 monocytes to adhering cells 
 
THP-1 cell adhesion was described previously (Crouse et al., 2009). Briefly, 
THP-1 cells were treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA, Sigma) 
for 24 hours, and cells incubated at 37oC, 5% CO2. Vehicle control was 0.0005% DMSO. 
After incubation, non-adherent cells in the supernatant were removed and adherent cells 
were washed with assay medium prior to 6-hour stimulation of cells with known TLR 
agonists or 15 μM Aβ(1-42). 
 To verify the extent of adhesion, a separate well containing THP-1 cells was 
induced with PMA, as described above. After incubation, non-adherent cells were 
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removed, and adherent cells were washed with PBS. The adherent cells were removed 
from the bottom surface of the cell-culture plate with 0.25% trypsin-EDTA (HyClone), 
and counted under a microscope using a hemocytometer. Percent adhesion was calculated 
by the number of adherent cells divided by the plated cell number. Adherent cells with % 
adhesion range of 75% and above were used for proinflammatory response experiments. 
 
2.5 LPS contamination assay 
 
To test the Aβ preparations for the presence of contaminating bacterial 
lipopolysaccharide, Aβ(1-42) was routinely tested using Polymyxin B-sulfate (PMX-B) 
(Sigma). THP-1 monocytes were prepared as described, and plated on a 48-well cell 
culture plate. Cells were pretreated with 0.1 μg/ml of PMX-B and incubated for 30 
minutes at 37oC, 5%CO2. After incubation, cells were treated with either 10 ng/ml of 
ultrapure LPS or 100 μmol/L of Aβ(1-42) and incubated further for 6 hours at 37oC. 
Following incubation, cell supernatants were collected, centrifuged as described above, 
and supernatants stored at -20oC prior to TNFα measurement. 
 
2.6 TLR antibody neutralization assay 
 
THP-1 monocytes or HEK293 cells were seeded in 48-well or 96-well cell culture 
plate, and pre-treated with 5-20 μg/ml of TLR antibodies, IgG isotype control or PBS for 
1 hour at 37oC, 5% CO2. TLR antibodies and IgG isotype controls that were utilized in 
this experiment were functional grade anti-human TLR2 (clone T2.5), TLR4 (clone 
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HTA125), CD14 (clone 61D3) antibodies, mouse IgG2,κ and IgG1,κ isotype controls 
from eBioscience (San Diego, CA), polyclonal anti-TLR2, TLR4, TLR1 or TLR6 
antibodies from InvivoGen, or rat IgG isotype control from Sigma. Following incubation, 
cells were treated with either 10 ng/ml ultrapure LPS, 1 ng/ml Pam3CSK4, 3 ng/ml (for 
THP-1 monocytes) or 1 ng/ml (for HEK293 cells) FSL-1, or 15 μmol/L of Aβ(1-42) and 
further incubated for 6 or 24 hours in the same conditions. After incubation, cell 
supernatants were collected as described above for TNFα or IL-8 determination.  
 
2.7 Measurement of proinflammatory products 
 
Secreted TNFα or CXC chemokine IL-8 in the supernatants were determined 
using Enzyme-linked immunosorbent assay (ELISA). ELISA has become a standard 
biochemical technique for determination of cytokine concentration, as well as levels of 
other proteins of interest, in body fluids and culture medium. An advantage of this 
method is its high specificity when monoclonal antibodies are used. Moreover, it is quick 
and easy to perform for large number of samples (Turner et al., 2004).  
100 μl of 2 μg/ml monoclonal anti-human TNFα/TNFSF1A primary antibody (for 
TNFα) or monoclonal anti-human CXCL8/IL-8 antibody (for IL-8) (R&D Systems, 
Minneapolis, MN, USA) was added to 96-well plates for overnight incubation at 24oC. 
Following incubation, wells were washed with PBS containing 0.05% Tween-20 and 
blocked with 300μL PBS containing 1% bovine serum albumin (BSA), 5% sucrose, and 
0.05% NaN3 for 1 hour at 24oC. After washing, 50μL of standards or cellular supernatant 
samples were added and the plate further incubated for 2 hours. After successive washing 
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and additions of 100μL of 0.1 μg/ml biotinylated anti-human TNF-α/TNFSF1A detection 
antibody (TNFα) or biotinylated anti-human CXCL8/IL-8 antibody (IL-8) (R&D 
Systems) in 20mmol/L Tris with 150mmol/L NaCl and 0.1% BSA for 2 hours, 100μL of 
streptavidin-horseradish peroxidase (R&D Systems) diluted 200 times with PBS 
containing 1% BSA for 20 minutes, and 100μL of equal volumes of 3,3’,5,5’-
tetramethylbenzidine and hydrogen peroxide (KPL, Gaithersburg, MD, USA) for 30 
minutes, the reaction was stopped by the addition of 1 mol/L H2SO4 solution. The optical 
density of each sample was analyzed at 450 nm with a reference reading at 630 nm using 
a SpectraMax 340 absorbance plate reader (Molecular Devices, Union City, CA, USA). 
A TNFα or IL-8 standard curve, with a range of 15 pg/ml to 2000 pg/ml is used to 
calculate the actual TNFα or IL-8 in the experimental samples. We made certain that the 
optical density of each sample falls within the standard curve. Samples whose optical 
density is outside the standard curve were diluted. 
 
2.8 Cell viability assay 
 
Powdered XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-
carboxanilide) (Sigma) was dissolved in RPMI 1640 medium without phenol red 
(HyClone) supplemented with 2 mmol/L L-glutamine to make a stock solution of 1 
mg/ml. The stock solution was kept at -20oC prior to use.  
For assessing the viability of THP-1 monocytes, the cells were plated in a 96-well 
cell culture plate and treated with effectors as described in section 2.3. After incubation, 
≈60ml of cell supernatants were treated with 30 ml of thawed 1 mg/ml XTT stock 
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solution containing 24.9 μmol/L of phenazine methosulfate (PMS) (Fisher Scientific) and 
cells further incubated for 3 hours at 37oC, 5% CO2.  
For HEK293 cells, cells were plated in a 96-well cell culture plate and treated 
with effectors as described. Following the desired incubation time, cell supernatants were 
removed and adherent cells were washed with corresponding assay medium. After 
removal of the medium, adherent cells were resuspended in 100 ml of HEK293 assay 
medium containing 0.33 mg/ml XTT and 8.3 μmol/L PMS. Cells were incubated further 
for 3 hours at 37oC, 5% CO2. 
For both cases, cell supernatants were removed from individual wells after 
incubation, centrifuged at 2500 xg for 10 minutes to remove cells, and supernatants 
transferred to a new 96-well plate. XTT reduction was analyzed by reading the 
absorbance of the solution at 467 nm. 
Tetrazolium salts, such as XTT, are commonly used as a measure of the redox 
potential of cells as a measure of their viability (Braeckman et al., 2002). It is based on 
the reduction of the colorless XTT tetrazolium salt within active mitochondria of living 
cells by succinate dehydrogenase to form an orange-colored water-soluble formazan 
(Figure 2.4) (Braeckman et al., 2002; Brady et al., 2007). The formation of a water-
soluble formazan allows direct monitoring of its appearance, and thus, is one of the 
advantages of XTT over other previous tetrazolium salts like MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), which produces insoluble salt 
when reduced (Scudiero et al., 1988; Kuhn et al., 2003).  
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Figure 2.4. Conversion of XTT to a water-soluble formazan salt by 
viable cells. Metabolically active cells cleave the yellow tetrazolium salt 
XTT to form an orange formazan dye.  XTT reduction is measured by 
reading the optical density at 467 nm. 
 
XTT                                                                                        Formazan 
  81
2.9 Atomic Force Microscopy 
 
At different aggregation states of the peptide, samples of Aβ(1-42) or Aβ(1-40) 
(100 μmol/L and 1 mmol/L) solutions were obtained and diluted to 1 μmol/L in water. 
Grade V1 mica (Ted Pella, Inc., Redding, CA, USA) was cut into 11 mm circles and 
affixed to 12 mm metal discs. 50 μL of resulting Aβ aliquots were applied to freshly 
cleaved mica, allowed to adsorb for 15 minutes, washed twice with water, air dried, and 
stored in a container with desiccant. Images were obtained with a Nanoscope III 
multimode atomic force microscope (Digital Instruments, Santa Barbara, CA, USA) in 
TappingModeTM. Height analysis was performed using Nanoscope III software on 
flattened height mode images. 
 
2.10 Statistical Analysis 
 
Data are expressed as mean ± SD. Statistical comparisons were made using 
Student’s t test (SAS system) (Harris, 2003). Differences between mean were considered 
significant at p<0.05. 
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3 MODULATION OF AMYLOID BETA AGGREGATION MORPHOLOGY AND ITS 
EFFECT ON PROINFLAMMATORY RESPONSE OF THP-1 MONOCYTES 
 
 
3.1 Introduction 
 
The brains of individuals with AD are characterized by the presence of two 
lesions: extracellular deposits of Aβ peptides, so-called neuritic or senile plaques, and 
intracellular neurofibrillary tangles (NFT) of hyperphosphorylated tau (Selkoe, 2001). 
Numerous studies have now shown that Aβ plays a very important role in the AD 
pathogenesis (Walsh et al., 2002a; Walsh et al., 2002b). Although the exact mechanism 
of neurodegeneration is still uncertain, substantial evidences associate Aβ as fundamental 
for neurodegeneration in AD (Ramsden et al., 2001). Particularly, several studies with 
synthetic Aβ pinpoint the fibrillar form similar to those present in amyloid-bearing 
plaques in AD as neurotoxic both in vitro and in vivo and causes neuronal dysfunction 
and loss in AD (Kowall et al., 1991; Pike et al., 1991; Lorenzo and Yankner, 1994; 
Iversen et al., 1995). However, recent reports suggest that it is the soluble, rather than the 
insoluble Aβ that is responsible for early dendritic and synaptic injury, and eventually 
neuronal dysfunction and degeneration (Lambert et al., 1998; Lue et al., 1999; Walsh et 
al., 2002a; Chromy et al., 2003; Bucciantini et al., 2004).  
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Besides being known to have direct neurotoxic effect, considerable evidences also 
favor an indirect effect of Aβ to neurodegeneration based on ability of Aβ to initiate and 
release inflammatory mediators and neurotoxic factors in microglia, such as secretion of 
proinflammatory cytokines, respiratory burst activity and increased phagocytosis and 
chemotaxis  (Murphy et al., 1998; Lue et al., 2001a; Lue et al., 2001b; Lee et al., 2002; 
Floden and Combs, 2006). Consistent with this, reactive microglia has been observed to 
be in and around Aβ – consisting plaques in AD (Frautschy et al., 1998; Stalder et al., 
1999). Thus, these studies suggest that the extracellular deposition of Aβ triggers 
inflammation in AD brain. 
However, despite numerous evidences connecting Aβ to neuronal injury and 
death, limited information is still available as to the exact mechanism by which Aβ 
causes neurodegeneration. Similarly, a more complicated question that is a focus of 
active study and debate is the question of, what Aβ assembly state correlates with the 
biological activity and contributes most critically to neurological decline in AD. It is thus 
important to have a clearer understanding of the Aβ structure-function relationship for the 
reason that determining the trigger of activation will result in a better understanding of 
the contribution of inflammation in AD, and subsequently, will have important 
implications to the development of therapeutic strategies. 
In this study we investigate the ability of synthetic Aβ peptides to invoke a 
proinflammatory response in a human monocytic cell line. Moreover, we seek to 
determine the active Aβ species that induces TNFα production in our THP-1 monocytes. 
We modulated Aβ aggregation by varying several factors including peptide 
concentration, peptide length and temperature to examine the Aβ assembly state that 
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correlates with biological activity. We propose that an Aβ (1-42)  fibrillar precursor was 
largely responsible for THP-1 cell activation. The data presented in this chapter is part of 
a collaborative study with Deepa Ajit of Department of Chemistry and Biochemistry, 
University of Missouri-Saint Louis. Additional data, analysis and conclusions will be 
presented and included in Ms. Ajit’s dissertation. 
 
3.2 Results 
 
3.2.1 Aβ aggregation and proinflammatory response 
 
To study the proinflammatory response of different Aβ aggregation species, we 
have utilized a well-studied mammalian cell system, THP-1 monocytes. Numerous 
investigators have utilized THP-1 cells as a model system for the study of 
proinflammatory production by LPS and Aβ, and have shown  that THP-1 cells are 
morphologically similar to microglia when stimulated with LPS and Aβ, making them a 
very good model of primary human microglia and for investigating Aβ induced 
inflammatory activity (Klegeris et al., 1997; Yates et al., 2000; Combs et al., 2001). We 
prepared the THP-1 monocytes as described in the methods, maintaining a cell 
concentration of 1x106 cells/ml. The lyophilized Aβ were resuspended in water to a final 
concentration of 100 μmol/L and kept at 4oC prior to cellular stimulation. The Aβ was 
allowed to aggregate at 4oC from 0h (freshly prepared) to 216h. In between these 
aggregation times, Aβ solution was removed and was used to stimulate the THP-1 
monocytes to a final Aβ concentration of 15 μmol/L. Cells were incubated for 6h at 37oC,  
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Figure 3.1 Proinflammatory activity of synthetic Aβ(1-42) at different 
aggregation. Aβ(1-42) was prepared in water and stored at 4oC , as described in 
the Methods. THP-1 monocytes were incubated with 100 μmol/L of Aβ(1-42) at 
different aggregation age to a final Aβ concentration of 15 μmol/L, and cells 
incubated for 6h at 37oC, 5% CO2. After post-incubation, supernatants were 
collected and TNFα production was measured using ELISA. Shown are three 
representative experiments from different Aβ(1-42) lots. 
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supplemented with 5% CO2. After incubation, supernatants were collected and assayed 
for TNFα production by ELISA. Figure 3.1 illustrates the  proinflammatory activity of  
different aggregates of 100 μmol/L Aβ. Minimal TNFα levels were produced when THP-
1 cells were treated with freshly reconstituted (0 hours) Aβ(1-42). However, a steady and 
significant increase in TNFα production was observed when Aβ(1-42) solution was 
allowed to aggregate further, with the peak TNFα level observed between 48h and 96h of 
Aβ aggregation. Interestingly, there was a noticeable decline in stimulatory activity when 
Aβ sample was incubated for a longer aggregation time. Different representative 
aggregation age profiles of 100 μmol/L of Aβ were included in the figure to illustrate that 
there is a lot-to-lot variation in stimulatory activity by synthetic Aβ (May et al., 1992; 
Zambrzycka et al., 2000). The toxicity of different Aβ aggregates were also monitored 
using XTT and results showed that 15 μmol/L Aβ aggregates were not toxic to THP-1 
cells (data not shown). 
We monitored the morphology of the Aβ aggregate species using AFM (Figure 
3.2a). The appearance of numerous punctuate species was observed for freshly 
reconstituted Aβ monomers, with height measurement of <2 nm for majority of the 
adsorbed species. There was also a noticeable presence of small spherical species in 
Aβ(1-42) at 0h of aggregation. Height analysis of these species ranged from 2 to 5 nm, 
with an average of 3.2 ± 0.8 nm (SD) for n = 115 measurements. This suggests that the 
said spherical species might be fibrillar precursors. Also, a number of bright spots, with 
height > 20nm, can be detected which may represent the formation of amorphous 
aggregates immediately following reconstitution of the peptide. Consequently, these 
spherical species were not able to stimulate THP-1 cells for TNFα production (Figure 
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3.1). The appearance of thin flexible fiber-like structures was observed at 48 hours of Aβ 
aggregation. Continuous incubation of Aβ increased the appearance of fibrillar structures. 
When applied to THP-1 cells, these Aβ species invoked TNFα production. Height 
measurements of the 48h aggregated Aβ fibrillar structure were performed and plotted as 
a histogram (Figure 3.2b) and fitted for multiple peaks. Using peak fitting analysis, we 
observed two populations: the first with a peak height and SE of 4.4 ± 0.1 nm, and the 
second having a mean height and SE of 7.9 ± 0.6 nm (Udan et al., 2008). Our height 
measurements for the fibers formed at 48h were in agreement with previous AFM 
measurements describing type I and type II fibrillar Aβ (Harper et al., 1997; Stine et al., 
2003). Further incubation of the Aβ samples (216 hours) resulted in the formation of 
longer fibrillar structures. Interestingly, a marked decrease in the presence of spherical 
species was observed at this incubation time.  The longer, more mature fibril structures 
present at 216 hours surprisingly were not able to stimulate the THP-1 cells in producing 
TNFα. 
We also varied the length of cell exposure to further analyze Aβ-induced 
proinflammatory production. We found that maximum TNFα production was achieved 
when THP-1 cells were exposed to 15 μmol/L of Aβ(1-42) for 10 hours (Figure 3.3a). 
This trend was slightly different from that of LPS - and Pam3CSK4 - treated THP-1 cells 
in that the maximal TNFα response was consistently observed after 6 hours of post-
stimulation (Figure 3.3b). Because continual exposure of the cells to proinflammatory 
products may have a toxic effect on the cells, we have utilized a 6-hour cell exposure 
despite the observed maximal Aβ TNFα response at 10 hour post stimulation. 
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Figure 3.2. Morphological studies of Aβ(1-42) aggregated species. (A) Aβ 
aggregation solutions (100 μmol/L) in water were prepared as described in 
Methods, and allowed to aggregate at 4oC. Aliquots were removed at 0, 48, 96 
and 216h, diluted to 1 μmol/L with water and imaged by AFM. Representative 
Aβ solutions were also used to treat THP-1 monocytes for TNFα production. 
AFM images are 5μm x 5μm and are shown in ‘height’ mode. (B) Representative 
frequency histogram from 300 height measurements of Aβ(1-42) aggregated at 
48h. Graph was fitted (r2 = 0.932) to a two-peak Gaussian area curve using 
PeakFit software v3.0 (Systat Software, Inc., San Jose, CA, USA).  AFM images 
courtesy of Ms. Deepa Ajit, Univ. of Missouri-St. Louis. Frequency histogram 
analysis courtesy of Dr. Michael R. Nichols, University of Missouri-St. Louis. 
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Figure 3.3. Effect of exposure time on Aβ(1-42)-, LPS- and Pam3CSK4- 
induced TNFα response in THP-1 cells. (A) THP-1 cells were exposed to 
15 μM Aβ(1-42) at given times. After post-incubation, TNFα production was 
analyzed by ELISA. (B) THP-1 cells were exposed to 10 ng/ml ultrapure E. 
coli K12 LPS or 1 ng/ml Pam3CSK4 at given times. Supernatants were 
collected after stimulation and assayed for TNFα. For both figures, TNFα 
was expressed as % of the maximum response, which was at 10 hours for 
Aβ(1-42), and 6 hours for LPS and Pam3CSK4. Error bars for Aβ are 
standard error for n = 6 trials for 0, 6, 10 and 24h and n = 3 for 48h; and n = 
3 for both LPS and Pam3CSK4. Actual maximum averaged TNFα levels are 
507 pg/ml for Aβ, 674 pg/ml for ultrapure LPS and 214 pg/ml for 
Pam3CSK4.  
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3.2.2. Modulation of Aβ aggregation 
 
Our data suggests that an intermediate Aβ(1-42) species is stimulating our THP-1 
monocytes in producing TNFα. However, as the Aβ aged, the species that were produced 
failed to invoke TNFα production. To further understand the inability of the later 
aggregated species to induce proinflammatory response in our THP-1 monocytes, we 
regulated the aggregation kinetics. Several factors can modulate in vitro Aβ fibril 
formation. One of the factors that affects Aβ fibrillogenesis is the peptide concentration 
(McLaurin et al., 2000; Taylor et al., 2003). Increasing the peptide concentration 
considerably enhances the rate of aggregation (Harper et al., 1999; Nilsson, 2004; Chen 
and Glabe, 2006). For this study, we increased the concentration of Aβ(1-42) stock 
solution from 100 μmol/L to 1.2 mmol/L, and followed the ability of the Aβ aggregation 
species to invoke TNFα production in THP-1 monocytes. To compare the effect of 
concentration, the THP-1 cells were treated with both the concentrated Aβ sample and 
100 μmol/L Aβ preparation, to a final concentration of 15 μmol/L. As shown in Figure 
3.4a, 1.2 mmol/L Aβ sample invoked TNFα production (24 pg/ml) when it was freshly 
reconstituted; however, further aging of the concentrated Aβ samples eradicated 
induction of TNFα response. This response was significantly different from that of 100 
μmol/L of Aβ, wherein the peak response was observed at 96h of Aβ aggregation. AFM 
analysis of the 1.2 mmol/L Aβ solutions revealed that aside from the globular species, the 
freshly reconstituted peptide solution (Figure 3.4b) already formed numerous long 
fibrillar structures. A longer, intertwined dense population of fibrils was observed as  
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Figure 3.4. Proinflammatory activity and morphological studies of  
concentrated Aβ (1-42) sample. (A) Unlike 100 μM of Aβ (black line), a more 
concentrated 1.2 mM Aβ(1-42) (circles) failed to induce TNFα response in 
THP-1 monocytes. Aβ was reconstituted in water to a final concentration 1.2 
mM, as described in Methods. THP-1 cells were treated with Aβ solution at 
different aggregation times, and cells incubated for 6h at 37oC. After 
incubation, cell supernatants were analyzed for TNFα using ELISA. A 
representative graph for 100 μM Aβ from Figure 3.1 was included for 
comparison. (B) AFM of freshly reconstituted and 24h aggregated 1.2 mM Aβ 
showed a population of fibrillar species. AFM was done as described in 
methods. AFM images courtesy of Deepa Ajit, University of Missouri-St. 
Louis. 
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early as 24 hours of Aβ aggregation, however, these species were not able to invoke 
TNFα response. It was not possible to do height analysis on fibrils at 24 hours of 
aggregation due to overabundance of intertwined fibrils. Nevertheless, the presented data 
suggest that a 12-fold increase in Aβ concentration rapidly diminishes the lag phase for 
fibril formation, and also attenuates the ability to induce TNFα response.  
We next studied the effect of Aβ incubation temperature in fibril formation and 
analyzed the biological activity of the Aβ species that are formed. We resuspended Aβ(1-
42) in water, as described in Methods, to a final concentration of 100 μmol/L and let the 
solution aggregate at 4oC, 25oC and 37oC. At different times, solutions were removed and 
used for THP-1 treatment. As shown in Figure 3.5a, only the Aβ species formed at 4oC, 
and not at 25oC and 37oC, induced TNFα production in THP-1 monocytes. There was a 
slight increase in the signal of Aβ at 25oC aggregated for 48 hours, but the increase was 
not significant. AFM analysis of freshly prepared Aβ solutions contained spherical 
species (Figure 3.5b), which were still present at 48 hours of aggregation for Aβ stored at 
4oC, along with a few fibrillar structures. Aβ solution incubated at 25oC and 37oC quickly 
formed longer fibrillar structures (data not shown). At 96 hours of aggregation, Aβ 
incubated at 4oC contained long flexible fibrils (Figure 3.5b) with a mean height of 5.5 ± 
1.6 nm (SD), as well as numerous globular structures, which correspondingly elicited an 
increased TNFα production in THP-1 cells. Aβ samples incubated at 25oC showed longer 
fibrils, with mean height of 6.9 ± 2.1 nm (SD). Interestingly, a decrease in the presence of 
globular structures was also noticeable. Aβ samples at 37oC aggregated much faster, as 
shown by an abundance of fibrils formed at 96 hours of aggregation.  These data further 
suggest that an intermediate fibrillar Aβ species induced TNFα response in THP-1 cells. 
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Figure 3.5. Accelerated aggregation of Aβ(1-42) by increasing the incubation 
temperature failed to invoke TNFα response in THP-1 monocytes. (A) 100 
μM Aβ(1-42) was prepared in water and incubated at 0oC (circles) , 25oC 
(triangles) or 37oC (diamonds). THP-1 cells were incubated with Aβ solutions to 
a final concentration of 15 μM for 6 hours, as described in Methods. After 
incubation, TNFα was assessed by ELISA. (B) Representative AFM images of 
freshly prepared (a-c) or 96-hour aggregated (d-f) Aβ(1-42) solutions incubated 
at 4oC (a,d), 25oC (b,e) or 37oC (c,f) were analyzed as described. Only the Aβ 
sample incubated at 4oC elicited TNFα response in THP-1 monocytes. AFM 
images courtesy of Deepa Ajit, University of Missouri-St. Louis.   
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Increased fibril formation diminished the TNFα response, and prolonged and accelerated 
aggregation failed to induce TNFα production in THP-1 cells.  
Aβ(1-42) and Aβ(1-40) are the most predominant variants of Aβ that are present 
in amyloid plaques (Taylor et al., 2003). The data that we have shown so far indicate that 
the active species of Aβ(1-42) was effective in inducing TNFα production in THP-1 
monocytes . We wanted to know if the species formed during Aβ(1-40) aggregation will 
also instigate TNFα response similar to that of Aβ(1-42). For this, we prepared 100 
μmol/L of Aβ(1-40) in water and treated the THP-1 cells the same way as Aβ(1-42). 
After 6 hours of post-incubation, supernatants were analyzed for TNFα. Our results 
showed that Aβ(1-40) samples at 4oC were not effective in inducing TNFα response 
(Figure 3.6a). Moreover, AFM imaging of the Aβ(1-40) aggregation at 4oC indicated a 
slower rate of fibril formation (Figure 6b, panels a-d). To hasten Aβ aggregation, samples 
of Aβ(1-40) were likewise incubated at 25oC or 37oC. AFM analysis showed that 
although at a much slower rate than Aβ(1-42), Aβ(1-40) also formed fibrils at elevated 
temperatures (Figure 3.6b, panels e-h, i-l) and longer Aβ incubation (Figure 6b, panels h 
and l). However, these species were ineffective in inducing TNFα release in THP-1 
monocytes (Figure 3.6a).  
 
3.3. Discussion 
 
Inflammation plays an essential role in the brain’s response to injury and 
pathology (Moore et al., 2002). Growing evidences have linked inflammation with the 
development of AD. Microglial cells, the resident immune cells of the CNS, play an  
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Figure 3.6. Aβ(1-40) failed to induce proinflammatory activity on THP-1 cells. 
(A) 100 μM Aβ(1-40) was prepared in water, and incubated at 4oC (triangle) , 25oC 
(inverted triangle) and 37oC (diamond), as described in Methods. Different 
aggregation solutions were used to treat the THP-1 monocytes for 6 hours, and TNFα 
was analyzed after post-stimulation. (B) Representative AFM images of Aβ(1-40) 
samples at 4oC (a-d), 25oC (e-f) and 37oC (i-l) at different times. AFM images are 5 
μm x 5μm. AFM images courtesy of Deepa Ajit, University of Missouri-St. Louis. 
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integral role in inflammation. Moreover, activated microglial cells have been found to be 
closely associated with and the most prominent component of senile plaques (Combs et 
al., 2000; Masumura et al., 2000; Selkoe, 2001; Mattson, 2004). Numerous cellular 
studies using microglia and human macrophage/monocytes cell line have demonstrated 
that Aβ  peptides are able to induce these cells to produce significant amounts of 
proinflammatory cytokines and chemokines (Meda et al., 1995; Yan et al., 1996).  
In studying the correlation between different Aβ aggregation species and 
proinflammatory production, we have utilized THP-1 monocytes for the main reason that 
THP-1 cells have expanse properties that are analogous to microglia and mature 
phagocytes when treated with LPS and Aβ (Klegeris et al., 1997; Combs et al., 1999; 
Combs et al., 2000). Moreover, THP-1 cells express numerous surface markers such as 
CD11a, CD11b, CD11c, CD18, CD36, CD44 and Fc immunoglobulin receptors that are 
pronounced on macrophages and microglia (Klegeris et al., 1997). These metabolic and 
morphological similarities between human monocytic cell line THP-1 and microglia 
made the THP-1 an appropriate model for the study of Aβ-induced proinflammatory 
response in primary human microglia. 
We have shown that 100 μmol/L of Aβ(1-42) at 4oC was capable of invoking 
TNFα production in THP-1 monocytes. Although the observed maximum TNFα response 
varies from lot-to-lot preparation of Aβ, it was still apparent that an intermediate Aβ 
species activate the THP-1 monocytes and prolonged aggregation (216 hours) of the Aβ 
was ineffective in stimulating proinflammatory response. Furthermore, enhancing the rate 
of aggregation and fibril formation by manipulating several factors such as increasing the 
concentration (Fig. 3.4) or Aβ incubation temperature (Fig. 3.5) produced Aβ species that 
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were not able to induce proinflammatory response in our THP-1 monocytes. These data 
suggest that an intermediate Aβ structure, and not the more mature rigid fibrils, act as a 
proinflammatory stimulus.   
Atomic force microscopy (AFM) is an ideal tool to follow the early 
morphological changes in Aβ fibril formation (Stine et al., 1996). Several investigators 
have used this technique to understand the process of Aβ fibrillogenesis (Harper et al., 
1997; Kowalewski and Holtzman, 1999; Nybo et al., 1999; Mastrangelo et al., 2006). 
Since we are investigating the Aβ aggregation species that invokes proinflammatory 
response in our model THP-1 monocytes, it is imperative that we consistently produce an 
unaggregated starting material. We accomplished this by treating the Aβ with 
hexafluoroisopropanol (HFIP). HFIP is known to disrupt peptide-peptide interaction 
thereby disaggregating the pre-formed aggregates (Klein et al., 2004; Findeis, 2007). 
AFM analysis of our freshly reconstituted Aβ(1-42) samples at 4oC, 25oC and 37oC 
showed punctate structures that had height measurements of < 2nm,  which correspond to 
monomers (Klein et al., 2004). Moreover, small spherical structures with heights of 2-5 
nm were also observed along with the punctuate species. These species were thought to 
be prefibrillar precursors. These measurements correspond with the findings of Nybo et 
al. (1999) in their investigation of the early stages of Aβ(1-42) fibrillogenesis. They 
reported the earliest recognizable ultrastructure of Aβ as globular structures with mean 
height of 4-5 nm. Moreover, these structures appear to fuse and align in a row, which 
later becomes fibrils (Nybo et al., 1999). Our results showed that further incubation of 
Aβ(1-42) at 4oC resulted in formation of two populations of fibrils with mean heights of 
4.4 ± 0.1 nm (SE) and 7.9 ± 0.6 (SE). These measurements were consistent with that of 
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Harper and colleagues (1997) when they analyzed the early steps of Aβ formation in vitro 
by AFM. They reported height measurements of 7.3 ± 0.53 nm and 3.8 ± 0.43 nm for 
their Aβ(1-42) species, which correspond to type-1 and type-2 fibrils, respectively 
(Harper et al., 1997). Interestingly, these fibrils consistently stimulated our THP-1 cells in 
producing proinflammatory TNFα. More importantly, the more mature fibrils that we 
have generated in later Aβ aggregation were ineffective in stimulating a response. This 
further infers that the intermediate fibrillar aggregation structures of Aβ(1-42) promote 
TNFα secretion, and not the more mature fibrils. 
Unlike Aβ(1-42), our Aβ(1-40) preparations were ineffective in activating our 
THP-1 cells for TNFα response (Figure 3.6). Morphological analysis of these samples 
showed a very slow progression of fibril formation. Aβ(1-40) and Aβ(1-42) bear different 
biochemical properties. Numerous biochemical studies have demonstrated that Aβ(1-42) 
aggregates much more quickly than Aβ(1-40) (Burdick et al., 1992; Jarrett et al., 1993). 
Moreover, although there is more Aβ(1-40) that is being secreted, Aβ(1-42) is the major 
component of senile plaques (Miller et al., 1993), as substantiated by recent findings 
which showed that high levels of Aβ(1-40) alone do not result in observable amyloid 
pathology, while low levels of Aβ(1-42) result in a wide range of amyloid pathology 
(McGowan et al., 2005). These findings, together with our observation, suggest that 
Aβ(1-42) is a major causative agent in pathogenesis of AD due to its enhanced 
aggregation properties (Chen and Glabe, 2006). 
Although instrumental in surveying the morphology of the species formed during 
fibril formation, AFM analysis must be combined with other in vitro techniques that can 
further substantiate our finding that intermediate soluble fibrillar structures of Aβ induce 
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production of proinflammatory products. We have further characterized our Aβ 
preparation by centrifuging the Aβ samples that were aggregated for 72 or 96 hours at a 
speed of >100,000g for 1 hour. At this speed, all the rigid fibrillar structures would pellet 
down and only the soluble oligomers will remain in the solution (Walsh et al., 2002b; 
Klein et al., 2004; Irvine et al., 2008). After centrifuging the prepared Aβ solution, the 
supernatant was collected and tested for its ability to invoke proinflammatory response in 
THP-1 cells. Using AFM, we found that some fibrillar structures were still present in the 
supernatant after the Aβ samples were spun. Yet, supernatant still invoked a TNFα 
response (data not shown).  Furthermore, the aggregation species in the supernatant was 
recognized by OC antibody (data not shown). This antibody recognizes fibrils and 
fibrillar oligomeric species, which are described as small soluble aggregates that are 
arranged in a similar conformation as in fibrils (Kayed et al., 2007). Taken together, these 
additional results further confirm that a soluble fibrillar precursor species is the 
proinflammatory form of Aβ. This project was done in collaboration with Deepa Ajit. 
Several other biophysical methods were utilized for characterization of our bioactive Aβ 
species and these additional data are presented in her dissertation. 
Although numerous investigations have suggested that large fibrillar forms of Aβ 
can kill neurons (Kowall et al., 1991; Pike et al., 1993; Lorenzo and Yankner, 1994; 
Geula et al., 1998), accumulating evidence in vitro now demonstrate that the soluble 
assembly forms of Aβ are the key nurotoxic effectors in AD (Lambert et al., 1998; Walsh 
et al., 1999; Klein et al., 2004). The presence of soluble oligomeric Aβ assemblies have 
also been observed from the supernates of AD brain and extracts of amyloid plaques 
(Roher et al., 1996; Enya et al., 1999; McLean et al., 1999), which suggest that soluble 
  102
Aβ could be the earliest mediators of neuronal dysfunction. Aβ is capable of upregulating 
cytokine and chemokine expression by microglia and monocytes/macrophages (Meda et 
al., 1995; Yan et al., 1996; Klegeris et al., 1997); however, there are still conflicting 
discussions and debates as to whether it is the oligomers or fibrils that are more potent 
neurotoxins. Recent report by Sondag and colleagues (Sondag et al., 2009) showed that 
proinflammatory cytokine IL-6 production was significantly higher when microglial cells 
were stimulated with Aβ oligomers than with fibrils. However, their results also showed 
that Aβ fibrils are more potent in inducing expression of proinflammatory chemokine 
keratinocyte chemoattractant (KC, a mouse homologue of chemokine IL-8) than the 
soluble aggregates. These findings demonstrate the ability of Aβ to act as a 
proinflammatory stimulus in microglia, but more importantly, these results suggest that 
the expression and release of proinflammatory products may depend on the specific 
conformation of Aβ. Our present data reveal that cells of the monocytic origin respond to 
an intermediate soluble yet fibrillar form of Aβ, and not the later more mature fibrils, by 
secreting the proinflammatory cytokine,TNFα. Taken together, these evidences further 
accentuate the intricacy involved in studying the association of Aβ aggregation with the 
proinflammatory response in AD brain.  
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4 THE ROLE OF TOLL-LIKE RECEPTORS IN AMYLOID BETA(1-42) 
ACTIVATION OF THE INNATE IMMUNE RESPONSE 
 
4.1 Introduction 
 
The brains of individuals with Alzheimer’s disease contain reactive microglia and 
these immune cells cluster at sites of Aβ deposition (Akiyama et al., 2000; Perry et al., 
2003). Microglial activation is always associated with production of inflammatory 
products and mediators, which include complement proteins, cytokines and chemokines 
(Das and Potter, 1995; Yates et al., 2000). Extensive and compelling evidence shows that 
these activated microglia surround Aβ plaques (Miyazono et al., 1991; Frautschy et al., 
1998; Apelt and Schliebs, 2001; Wegiel et al., 2001) and in vitro activation of microglia 
by Aβ results in the production and secretion of proinflammatory molecules such as 
reactive oxygen species, cytokines and neurotoxins (Griffin et al., 1989; Venters et al., 
1999; Akiyama et al., 2000; Yates et al., 2000; Combs et al., 2001). However, it was 
difficult to ascertain whether Aβ-induced inflammation contributes to or causes AD. 
Several investigators have reported that the use of anti-inflammatory agents or non-
steroidal anti-inflammatory drugs (NSAIDs) significantly reduced the risk for AD 
(McGeer et al., 1996; Stewart et al., 1997; Rogers, 2008). These evidences strongly 
support the concept that chronic inflammatory process contributes to AD progression.  
Inflammation is considered to be a double-edged sword: it may be useful when 
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controlled, but deadly when it is not (Akiyama et al., 2000; Lai et al., 2006). Over the 
years, investigators have tried to answer the mechanism by which Aβ causes heightened 
expression of proinflammatory products in microglia. Some groups reported several 
inflammation-related receptors present in the microglia as key players in Aβ-induced 
microglial activation and inflammatory response. These include receptors for advanced 
glycosylated end-products (RAGE) (Yan et al., 1996), scavenger receptor class A (El 
Khoury et al., 1996; Paresce et al., 1996), B-class scavenger receptor CD36, intergrin 
associated protein/CD47 and α6β1-integrin receptor complex (Bamberger et al., 2003), as 
well as calcium-, protein kinase C-, and tyrosine kinase- dependent second messenger 
pathways (Klegeris et al., 1997; Combs et al., 1999; Yates et al., 2000). Recent studies by 
Fassbender and colleagues demonstrated that fibrillar Aβ interacts and binds with the 
bacterial lipopolysaccharide (LPS) receptor, CD14 (Fassbender et al., 2004). Moreover, 
Bate et al reported that the subsequent killing of Aβ-damaged neurons by microglia is a 
CD14 dependent process (Bate et al., 2004; Heneka and O'Banion, 2007). Furthermore, 
Liu et al demonstrated a direct role of CD14 in fibrillar Aβ(1-42) phagocytosis, and an 
observed elevation of CD14 immunostaining in AD brains compared with controls (Liu 
et al., 2005). These evidences connecting CD14 with Aβ strongly suggest that innate 
immunity is related to AD pathology.  
A wealth of data now indicates that CD14 interacts with TLR4 and TLR2 
(Chapter 1 review). In this study, we aspired to investigate and identify the 
transmembrane TLR(s) that may be involved in the induction of innate immune response 
by Aβ(1-42). For this investigation, we utilized cell systems including THP-1 monocytes 
as a model of primary microglia (Chapter 3 review), as well as human embryonic kidney 
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(HEK293) cells. We propose that TLR4 and TLR2 are highly involved in Aβ(1-42)-
induced proinflammatory cytokine production in these mammalian cell model systems.   
 
4.2 Results 
 
4.2.1 Mammalian cell model system: THP-1 monocytes 
 
4.2.1.1 Toll-like receptor ligands activate the proinflammatory response in THP-1 
monocytes 
 
The interaction of LPS with TLR4 is the best studied model of innate immunity 
(Aderem and Ulevitch, 2000). Several groups have extensively analyzed LPS-mediated 
TLR4 downstream signaling for induction of proinflammatory response (Poltorak et al., 
1998; Hoshino et al., 1999; Qureshi et al., 1999). Aside from TLR4, numerous studies 
also focused on TLR2 due to its capability to recognize a broad range of ligands (Chapter 
1 review; (Albiger et al., 2007)). We started our investigation by first testing whether 
THP-1 monocytes produce TNFα upon induction with known TLR agonists LPS (TLR4), 
synthetic tripalmytoyl cysteinyl seryl tetralysine Pam3CSK4 (TLR2/1) and synthetic 
diacylated lipopeptide FSL (TLR2/6). THP-1 monocytes were treated with increasing 
concentration of the agonists, and incubated for 6 hours, as discussed in Methods. 
Supernatants were collected after incubation, and secreted TNFα was measured by 
ELISA. TNFα measurements revealed a concentration-dependent response for all TLR 
agonists (Figure 4.1).  Fitting the data to a sigmoidal three-parameter equation produced 
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EC50 values of 5 ng/ml for ultrapure K12 LPS, 1 ng/ml for Pam3CSK4 and 7 ng/ml FSL-
1. For succeeding experiments, we decided to utilize the following concentrations: 10 
ng/ml LPS, 1 ng/ml Pam3CSK4 and 1 or 3 ng/ml FSL-1. We further extended our 
investigation by determining the best condition for maximal TNFα production by our 
TLR agonists. We found highest TNFα response for LPS, Pam3CSK4 and FSL-1 when 
cells were exposed to these agonists for 6 hours (Figure 3.3, FSL data not shown).  These 
data confirmed the responsiveness of THP-1 monocytes to known TLR ligands, and is 
particularly useful in our investigation of Aβ-TLR interaction since these agonists can be 
used in later experiments as positive controls. 
 
4.2.1.2 Amyloid beta(1-42) is devoid of any contamination 
 
We have previously shown that soluble fibrillar Aβ(1-42) activates THP-1 
monocytes for proinflammatory response (Chapter 3). In the previous report, we have 
demonstrated that the maximal TNFα response was achieved when 100 μmol/L Aβ(1-42) 
was allowed to aggregate at 4oC between 48 and 96 hours. Because of this result, the 
same conditions were utilized for the Aβ samples in this study. For every analysis, 
corresponding AFM images and height analyses were performed. Height measurements 
were in accord with the soluble fibrillar Aβ(1-42), discussed in chapter 3.  
Bacterial LPS utilizes TLR4 for activation of TLR downstream signaling that 
culminates in production of proinflammatory cytokines and chemokines such as TNFα. 
Because our main objective is to identify the TLR that plays a functional role in Aβ- 
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Figure 4.1. Known TLR agonists induce TNFα production in a dose-
dependent manner. THP-1 monocytes were stimulated with increasing 
concentration of ultrapure K12 LPS (circles), synthetic Pam3CSK4 
(triangles) or synthetic FSL-1 (diamonds) for 6 hours, as described in 
Methods. The same volume of water was added to the cells as a control 
in the absence of agonist. After stimulation, secreted TNFα in the 
supernatants was analyzed by ELISA. Error bars represent standard error 
for three measurements. Data was fit to sigmoidal three-parameter 
equation using SigmaPlot graphing program. 
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induced inflammatory response, we have to ensure that our Aβ(1-42) is devoid of any 
contaminating bacterial lipopolysaccharide that might interfere with the proper 
interpretation of our results. We also wanted to confirm that the secreted TNFα observed 
in THP-1 monocytes was due to Aβ as a proinflammatory stimulus, and not due to traces 
of contaminating bacterial LPS. To rule out the presence of traces of LPS in our Aβ(1-42) 
samples, we tested our Aβ preparation using the compound Polymyxin-B sulfate (PMX-
B). PMX-B is a cationic decapeptide that binds to lipid A moiety of LPS and neutralizes 
its pathogenicity and prevents LPS-induced cytokine production (Pristovsek and Kidric, 
1999). To determine if PMX-B can neutralize TNFα secretion by 10 ng/ml of ultrapure 
K12 LPS, THP-1 monocytes were pretreated with medium alone, or with increasing 
concentration of PMX-B for 30 minutes. After preincubation, cells were stimulated with 
10 ng/ml LPS for 6 hours prior to TNFα measurement. PMX-B effectively neutralized 
the proinflammatory effect of LPS in a dose-dependent manner, with a 2-fold reduction 
of LPS signal for as low as 10 ng/ml of PMX-B (Figure 4.2a). This data implies that 
PMX-B is an effective tool in neutralizing LPS response and thus, can be used to test for 
LPS contamination in our Aβ samples. Using XTT proliferation assay, it was found that 
PMX-B alone did not have any toxic effect on our THP-1 monocytes (data not shown). 
Next, we pretreated the THP-1 cells with 0.1 μg/ml of PMX-B for 30 minutes, as 
described previously, prior to THP-1 stimulation with 15 μmol/L of Aβ(1-42). Figure 
4.2b shows different profiles for PMX-pretreated Aβ and PMX-pretreated LPS (Udan et 
al., 2008). PMX-B almost completely abrogated the K12 LPS signal (LPS/PMX % 
response of 1.85 ± 0.84, as compared to 100 ± 1.1 % response by LPS alone), but with 
little or no effect on Aβ signal (Aβ/PMX % response of 95.7 ± 3.25 compared to 100 ± 
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Figure 4.2. PMX-B is a powerful tool for ruling out the presence 
of small traces of contaminating bacterial LPS. (A) The LPS 
proinflammatory response was neutralized by PMX-B in a dose-
dependent manner. THP-1 were preincubated with increasing 
concentrations of PMX-B prior to stimulation with 10 ng/ml LPS, as 
described in Methods. Error bars represent standard error for three 
experiments. (B) PMX-B does not have an effect on Aβ(1-42) 
proinflammatory response. THP-1 cells were treated with 15 μM Aβ 
or 10 ng/ml LPS in the presence or absence of 0.1 μg/ml of PMX-B. 
Results are presented as % TNFα of the Aβ or K12 LPS without 
PMX-B. Error bars represent standard errors for 15 trials in five 
separate experiments. Actual TNFα levels averaged 328 pg/ml for 
Aβ and 859 pg/ml for K12 LPS.  
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0.43 % response by Aβ without PMX-B). This signifies that our Aβ preparations are 
devoid of contaminating LPS. Moreover, the results imply that TNFα production in THP-
1 is mainly due to Aβ as a proinflammatory stimulus, and not because of possible traces 
of LPS in the Aβ preparation. For subsequent experiments involving Aβ, Aβ/PMX-B and 
LPS/PMX-B samples were included for continual monitoring of trace contamination. 
Some results showed greater than 10% reduction in Aβ- induced TNFα response when 
pretreated with PMX-B, although XTT cell proliferation experiments indicated that our 
Aβ samples are devoid of any bacterial contamination (data not shown). For accurate 
interpretation of results, those experiments were not included in the study of Aβ-TLR 
interaction.    
 
4.2.1.3 Toll-like receptor antibody neutralization assay was effective in blocking the 
activity of known TLR agonists bacterial LPS and synthetic Pam3CSK4 
 
We have developed a TLR antibody neutralization assay to aid us in investigating 
which transmembrane TLR mediates Aβ-induced immune response. We initially tested 
the effectiveness of this assay on our known TLR ligands, bacterial LPS (TLR4) and 
synthetic Pam3CSK4 (TLR2). THP-1 cells were preincubated with 10 μg/ml TLR 
antibodies prior to addition of either 10 ng/ml E. coli 026.B6 LPS or 1 ng/ml Pam3CSK4. 
TLR4 neutralization lowered the E. coli 026.B6 LPS response by almost 79% (% 
response of 29.3 ± 1.56 compared to 100 ± 2.9 of LPS alone) (Figure 4.3, gray bars). 
Surprisingly, TLR2 also had a significant effect on our LPS response. Antibody blockade 
of TLR2 considerably decreased the % LPS response to 33.2 ± 0.25. This result implies 
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Figure 4.3. Toll-like receptor (TLR) neutralization of bacterial 
lipopolysaccharide. THP-1 cells were pre-incubated with 10 μg/ml of TLR 
antibodies (eBioscience) or mouse isotype controls (IgG2 isotype control for TLR2 
and TLR4 antibodies, IgG1 isotype control for CD14) for 1 hour prior to addition of 
10 ng/ml LPS, as described in methods. Experiments done several times, and 
representative graph is shown. Pure LPS (E. coli 026.B6) (gray bars) utilized both 
TLR4 and TLR2 in secretion of TNFα. TLR2 conferred sensitivity to LPS may be 
due to contaminating bacterial lipoproteins. Repurified LPS preparation (E. coli 
K12) abolished the effect of TLR2 on LPS-induced TNFα response. Error bars are 
SE of three measurements.    
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that TLR2 lowered the TNFα response by almost 70%, similar to the effect of TLR4 
neutralization. Because substantial evidences show that LPS utilizes TLR4 for 
downstream activation of innate immunity, this finding was unexpected. Several 
investigators reported that TLR2-conferred sensitivity to LPS may be due to 
contaminating lipoproteins (TLR2 agonists) in commercially available LPS preparations 
(Kielian, 2006), and repurifying the LPS preparations and removal of trace amounts of 
TLR2 agonists abated the effect of TLR2 in LPS activation (Hirschfeld et al., 2000). 
Because of this possibility, we repeated the TLR neutralization using a commercially 
available repurified, ultrapure K12 LPS. This LPS preparation has undergone stringent 
repurification by double phenol extraction of a 0.2% triethylamine/0.5% deoxycholate 
aqueous phase which ensures removal of contaminating lipoproteins that signal through 
TLR2 ((Hirschfeld et al., 2000), InvivoGen.com). Our result (Figure 4.3, black bars) 
demonstrated a TLR4-, but not TLR2-, dependent LPS-induced TNFα production (% 
TNFα response of 13.0 ± 3.4 for TLR4, 87.9 ± 1.4 for TLR2). The TLR2 and TLR4 
isotype control IgG2 had 10% inhibitory effect (% response of 90.0 ± 2.4) on LPS 
response; this denotes that the 10% inhibitory effect observed on K12 LPS response 
when TLR2 was neutralized was not statistically significant. 
Pam3CSK4 utilizes TLR2 in activation of the innate immune response. This was 
clearly demonstrated by an almost complete eradication of Pam3CSK4- induced secreted 
TNFα when TLR2 was blocked by 10 μg/ml of the TLR2 antibody (Figure 4.4, gray bar; 
% response of 4.2 ± 0.76) (Udan et al., 2008). As expected, TLR4 is not being utilized by 
Pam3CSK4 for TNFα secretion (80.9 ± 1.4 % TNFα response). Although there is a 20% 
inhibitory effect of TLR4 neutralization in Pam3CSK4 response, the value was not 
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Figure 4.4 TLR antibody neutralization of bacterial lipopolysaccharide and 
Pam3CSK4. THP-1 monocytes were pre-incubated with 10 μg/ml of TLR 
antibodies (eBioscience) or isotype controls (IgG2 for TLR2 and TLR4 antibodies; 
IgG1 for CD14) as described in Methods, prior to treatment with either 10 ng/ml of 
ultrapure E. coliK12 LPS (black bars) or 1 ng/ml Pam3CSK4 (gray bars). Secreted 
TNFα was measured by ELISA. Results are presented as % TNFα of LPS or 
Pam3CSK4 pre-incubated with phosphate-buffered saline (PBS) medium. Actual 
TNFα levels were 216 pg/ml for LPS and 257 pg/ml pg/ml for Pam3CSK4. Error 
bars for LPS data correspond to SE for six trials (2 experiments), and three trials, 
one experiment for Pam3CSK4 data. A Student’s t-test was used to calculate the 
significance between individual TLR and their respective isotype IgG controls ( *p 
< 0.001 and #p < 0.0025) 
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statistically different (p< 0.25) from the TLR2 IgG2 isotype control (% response of 85.6 
± 4.6).   
This experiment also demonstrated the necessity of the accessory protein CD14 
for ultrapure LPS- and Pam3CSK4- induced activation of downstream TLR signaling. 
K12 LPS response was significantly attenuated by CD14 antibody, as shown by 75% 
inhibition. This result was significantly different from the CD14 isotype control IgG1 
which inhibited only 6% of the K12 LPS response. Likewise, neutralization with the 
CD14 antibody blocked 90% of Pam3CSK4 signal. The data presented here indicates that 
the developed TLR neutralization assay is sensitive in specific recognition of TLR 
agonists and may be a tool for invetistigating Aβ-TLR interaction. 
 
4.2.1.4 TLR2 and TLR4 play a role in fibrillar Aβ(1-42)-induced TNFα response in THP-
1 monocytes 
 
TLR neutralization was performed to clarify which TLR is being utilized by 
fibrillar Aβ for TNFα production. As described in methods, THP-1 cells were incubated 
with 10 μg/ml of TLR antibodies or isotype control for 1 hour prior to stimulation with 
15 μmol/L of Aβ(1-42). Our results demonstrated the importance of TLRs and TLR 
accessory protein CD14 for Aβ-induced activation of innate immune response. As shown 
in Figure 4.5, CD14 neutralization significantly reduced Aβ response by 62%, relative to 
its isotype control IgG1 (Udan et al., 2008). This result suggests that Aβ utilizes CD14 
for TNFα production, which was in accord with the previous report (Fassbender et al., 
2004). Surprisingly, both TLR2 and TLR4 neutralization also diminished Aβ- induced 
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TNFα response. TLR4 blockade decreased the TNFα response by 35% (% response of 
65.45 ± 1.87). More surprisingly, TLR2 antibody was more effective in neutralizing the 
Aβ response, as evidenced by 50% attenuation of TNFα signal (% response of 50.62 ± 
3.26). Using Student’s t-test, these results were significantly different from IgG control (p 
< 0.001).  
The TLR2 and TLR4 antibodies (InvivoGen) that were used in this experiment 
were different from the ones used for TLR neutralization of LPS and Pam3CSK4. This is 
due to a consistent significant attenuation of Aβ response by IgG2 control used in LPS 
and Pam3CSK4 studies. Nevertheless, this different set of TLR antibodies was still 
effective in blocking TLR. Moreover, a consistent 20 – 30% increase in Aβ response was 
observed when THP-1 monocytes were pre-treated with 10 to 20 μg/ml of CD14 isotype 
control, IgG1 (Figure 4.5 and 4.6b). This consistent stimulation may have cancelled out 
some of the effectiveness of anti-CD14 neutralization. Because of the IgG effect, it was 
not possible to compare the differences between TLR2, TLR4 and CD14 antibody 
neutralizing ability of Aβ response.  
The Aβ-induced TNFα response was neutralized by TLR antibodies in a dose-
dependent manner (Figure 4.6 a and b) (Udan et al., 2008). The effectiveness of TLR 
antibodies in neutralizing Aβ response was clearly demonstrated when THP-1 cells were 
pre-treated with as low as 5 μg/ml TLR antibodies. About 29% reduction of TNFα 
response was observed when THP-1 cells were treated with 2.5 μg/ml of TLR2 antibody, 
and 15% reduction of TNFα response for TLR neutralization. Increasing the 
concentration of the TLR antibodies augmented the effectiveness of neutralization, as 
depicted by a more dramatic decrease in TNFα response. A boost of TLR2 or TLR4 
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Figure 4.5. TLR2, TLR4 and CD14 play an active role in Aβ-induced innate 
immune response activation. THP-1 monocytes were pre-incubated with 10 
μg/ml of TLR2, TLR4 (InvivoGen), CD14 (eBioscience) antibodies, or IgG isotype 
controls, as described in Methods. Isotype controls were rat IgG (Sigma) for TLR2 
and TLR4, and mouse IgG1 (eBioscience) for CD14. After incubation, THP-1 cells 
were stimulated with 15 μM of Aβ(1-42) for 6 hours. TNFα was measured using 
ELISA. Results are expressed as % TNFα of Aβ response treated with phosphate 
buffered saline (PBS) medium. 20-30% stimulation of Aβ response was 
consistently observed for IgG1. Actual TNFα levels induced by Aβ alone averaged 
328 pg/ml. Error bars correspond to SE for 12 trials (four separate experiments) for 
TLR2, TLR4 and rat IgG, and six trials (2 experiments) for CD14 and mouse IgG1. 
A Student’s t-test was used to calculate the significance between individual TLR 
and their respective isotype IgG controls ( *p < 0.0001). rIgG; rat IgG 
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Figure 4.6. Dose-dependent neutralizing ability of TLR antibodies against Aβ(1-
42). THP-1 cells were pre-incubated for 1 hour with increasing concentrations of 
TLR antibodies or their isotype controls, as described in the Methods, prior to 
stimulation with 15 μM of Aβ(1-42). After 6 hours post-stimulation, TNFα was 
measured using ELISA. Results are expressed as % TNFα of Aβ response treated 
with phosphate buffered saline (PBS) medium. (A) TLR2 (circles) and TLR4 
(triangles) antibodies (InvivoGen) blocked Aβ response in a dose-dependent manner. 
Rat IgG (rIgG, squares) is the isotype control for TLR2 and TLR4. The 10 μg/ml 
TLR and IgG result are reproduced from Figure 4.5. Standard errors are SE for n = 3 
trials (5 μg/ml) and n = 6 trials (20 μg/ml). A Student’s t-test was used to calculate 
the significance between individual TLR and their respective isotype rat IgG (*p < 
0.0001). Actual TNFα was the same as Figure 4.5 (B) CD14 (circles) antibody 
(eBioscience) also efficiently blocked Aβ response in a dose-dependent manner.   
Error bars are SE of three trials. Actual TNFα of Aβ alone averaged 170 pg/ml 
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concentration from 10 μg/ml to 20 μg/ml further lowered the TNFα response by 10%. On 
the other hand, the neutralizing effect of CD14 antibody on Aβ appeared to plateau at ~45 
± 3.0% starting at 5 μg/ml. The TLR2 and TLR4 isotype control rat IgG did not have an 
effect on Aβ response. However, a consistent stimulation of the response was observed 
for CD14 isotype control mouse IgG1. Moreover, similar with the results for 
neutralization using 10 μg/ml TLR antibodies, TLR2 antibody was more effective in 
blocking Aβ response than TLR4.  Nevertheless, the results presented here suggest that 
Aβ is utilizing multiple toll receptors for the activation of innate immune response. More 
importantly, TLR2 and TLR4 play an active role in Aβ-induced production of 
proinflammatory products. Noticeably, a complete abrogation of the Aβ-induced immune 
response was not observed when higher concentrations of TLR antibodies were used. 
Individual TLR neutralization using 20 μg/ml antibodies caused only 50-70% inhibition. 
A number of reasons may explain this result. First, previous reports suggested that Aβ 
fibrils also interact with other receptors for cellular activation and neurotoxicity like 
scavenger receptors, RAGE, CD11b/CD18receptor, CD36/α6β1-integrin/CD47 
multireceptor complex or complement factor C1 (Bamberger et al., 2003; Fassbender et 
al., 2004). Thus, to explain the remaining unblocked activity, it is possible that Aβ 
utilized these other receptors when TLRs were made unavailable. 
A second possibility may be that since TLR2 and TLR4 play a role in Aβ 
response, one receptor may compensate for the other when one is inaccessible. We tested 
this hypothesis by using a combination of TLR2, TLR4 and CD14 antibodies to 
investigate whether neutralizing multiple receptors will further enhance the reduction of 
TNFα response as compared to individual receptor blockade. For this study, we lowered 
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our TLR antibody concentration to 5 μg/ml to better observe the effect of combination 
antibody treatment. Moreover, we also supplemented each cell treatment with up to 10 
μg/ml of rat IgG or 5 μg/ml of mouse IgG1 to match the triple combination 
TLR2/TLR4/CD14 neutralization with isotype control amounts. Since we have used a 
lower antibody concentration, and individual TLR neutralization was supplemented with 
IgG isotype controls, it is not possible to directly compare the results that we obtained in 
this experiment with that in Figure 4.5 and Figure 4.6. This experiment was performed 
numerous times and the results are shown in Figure 4.7 (Udan et al., 2008). As shown, 
the Aβ-induced TNFα response was only slightly reduced when individual TLRs were 
blocked with 5 μg/ml of  the antibody (% response of 92.6 ± 0.72, 85.2 ± 3.73 and 98.52 
± 1.57 for TLR2, TLR4 and CD14, respectively). These individual TLR neutralization 
results were not statistically different from that of the mouse IgG1/rat IgG control (% 
response of 95.2 ± 2.7). As discussed earlier (Figures 4.5 and 4.6), a consistent 
enhancement of Aβ response was observed when cells were treated with mouse IgG1 
control. Since the individual TLR2 and TLR4 (and all other samples that do not contain 
CD14) were supplemented with mouse IgG1 to match the concentration of the triple 
combination TLR2/TLR4/CD14, this may have masked some of the TLR blocking 
activity. A double combination of TLR2/CD14 and TLR4/CD14 antibody neutralization 
was better in lowering the Aβ response compared to the individual TLR blockade (34.4% 
and 35.5% reduction, respectively). The neutralizing activity of TLR2/CD14 and 
TLR4/CD14 compared to that of mouse IgG1/ rat IgG control was significantly different 
(p<0.001). These comparable results of TLR2/CD14 or TLR4/CD14 blockade suggest 
that an overlap to some extent of Aβ interaction with both TLRs and CD14 may be 
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Figure 4.7. Combination TLR antibody neutralization of Aβ(1-42)-induced TNF α 
response. THP-1 monocytes were pre-incubated with 5 μg/ml of TLR2, TLR4 
(InvivoGen), CD14 (eBioscience) antibodies, or a combination of 5 μg/ml mouse IgG1 
and 10 μg/ml rat IgG isotype control, as described in Methods. Individual cell 
treatments were also supplemented with one or both of the mentioned IgGs to match 
the concentration of the IgG controls. After pre-treatment, THP-1 cells were stimulated 
with 15 μM of Aβ(1-42) for 6 hours. TNFα was measured using ELISA. Results are 
presented as % TNFα of Aβ response treated with phosphate buffered saline (PBS) 
medium. Actual TNFα levels induced by Aβ alone averaged 487 pg/ml. Error bars 
correspond to SE for n = 3 trials. A Student’s t-test was used to calculate the 
significance between individual TLR and the mouse IgG1/rat IgG isotype control ( *p 
< 0.001). Less significant differences were observed for individual anti-TLR2 (p< 
0.25), anti-TLR4 (p< 0.05) and anti-CD14 (p< 0.20) antibody treatments.  rIgG; rat 
IgG, mIgG1; mouse IgG1 
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occurring. Blocking both TLR2 and TLR4 simultaneously (TLR2/TLR4) was much more 
effective in neutralizing the response (60% reduction). The most effective reduction of 
Aβ response was observed when all TLR2, TLR4 and CD14 (TLR2/TLR4/CD14 triple 
combination) were neutralized (71.3% reduction, compared with the mouse IgG1/rat IgG 
isotype control).  
 
4.2.1.5 TLR1 and TLR6 may also be involved in fibrillar Aβ(1-42)-induced activation of 
the innate immune response 
 
We have so far demonstrated that TLR2 plays an active role in Aβ-induced 
initiation of innate immune response. TLR2 forms a TLR2/TLR6 or TLR2/TLR1 
heterodimer to recognize diacylated and triacylated lipopeptides (LPT), respectively 
(Nakata et al., 2006). To assess if TLR2 also requires complex formation with either 
TLR1 or TLR6 for recognition of fibrillar Aβ, we have included TLR1 and TLR6 
antibodies in our TLR neutralization analysis.  
To test the effectivity of the added antibodies, we performed neutralization assay 
using the known TLR2 agonists, Pam3CSK4 (for TLR2/1) or FSL-1 (for TLR2/6) (Figure 
4.8). Unlike the previous neutralization experiment for TLR ligands (Figure 4.3 and 4.4), 
we lowered our TLR antibody concentration to 1 μg/ml in this study to better assess the 
effect of the antibody neutralization, since using 10 μg/ml of the TLR1 or TLR6 antibody 
completely eradicated the agonist signals (data not shown). As described in Methods, 
THP-1 cells were pre-incubated with TLR antibodies or isotype control for 1 hour prior 
to 6-hour cellular stimulation with Aβ(1-42). Results clearly showed that triacylated 
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Figure 4.8. TLR2 complex antibody neutralization of known TLR2 
agonists, synthetic diacylated or triacylated lipopeptides. THP-1 monocytes 
were pre-incubated with 1 μg/ml of TLR antibodies (InvivoGen) or its isotype 
control rat IgG (Sigma) for 1 hour, prior to 6-hour cellular stimulation with 
either 10 ng/ml of FSL-1 (black bars) or 1 ng/ml of Pam3CSK4 (gray bars). 
Secreted TNFα was measured by ELISA. Results are presented as % TNFα of 
FSL-1 or Pam3CSK4 pre-incubated with phosphate-buffered saline (PBS) 
medium. Error bars represent SE for nine trials. A Student’s t-test was used to 
calculate the significance between individual TLR and their respective isotype 
IgG controls ( *p < 0.001) 
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synthetic Pam3CSK4 activates downstream immune signaling via TLR2/TLR1 
heterodimers. A significant 60% and 75% reduction in TNFα response were observed 
when TLR2 and TLR1 were neutralized, respectively (p< 0.001). Antibody blockade of 
TLR6 lowered the Pam3CSK4- induced secretion of TNFα by 13% (% response of 86.9 ± 
1.9); however, this result was not significantly different from that of its isotype control rat 
IgG (% response of 87.65 ± 2.4). Likewise, diacylated synthetic FSL-1 utilizes 
TLR2/TLR6 complex for activation of downstream signaling, as depicted by 71% and 
91% reduction in TNFα response when TLR2 and TLR6 were blocked with 1 μg of the 
antibody, respectively.   
Next, the TLR antibody neutralization experiment was utilized to answer the 
question: is TLR2/TLR1 or TLR2/TLR6 complex formation required for Aβ-induced 
activation of the innate immune response, or does Aβ interact with TLR2 alone? For this 
study, we have reverted back to using 10 μg/ml of the TLR antibodies. For the purpose of 
investigating the importance of TLR2 complex formation, we have included combination 
neutralization of TLR2/TLR1 and TLR2/TLR6 in our neutralization experiment. The cell 
treatments with individually blocked TLRs were supplemented with 10 μg/ml of the 
isotype rat IgG control to match the concentration of double combination TLR2/TLR1 or 
TLR2/TLR6 with isotype control amounts.  Our preliminary results suggest that TLR1 
and/or TLR6 may also have an active role in Aβ response (Figure 4.9). Neutralizing 
TLR2 with 10 μg/ml of the antibody decreased the Aβ-induced %TNFα response to 39.9 
± 2.6 (70% reduction). Surprisingly, blocking either TLR1 or TLR6 also significantly 
lowered the TNFα response, compared to the isotype rate IgG (p< 0.001). TLR1 was 
much more effective in neutralizing the Aβ signal than TLR6, as shown by 57%  
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Figure 4.9. Combination TLR2 complex antibody neutralization of Aβ(1-
42)-induced TNF α response. THP-1 monocytes were pre-incubated with 
10 μg/ml of TLR2, TLR1, TLR6 (InvivoGen) antibodies, or 20 μg/ml rat IgG 
isotype control for 1 hour, as described in Methods. Individual cell 
treatments were also supplemented with 10 μg/ml of rat IgG to match the 
concentration of the 20 μg/ml rat IgG control. After pre-treatment, THP-1 
cells were stimulated with 15 μM of Aβ(1-42) for 6 hours. TNFα was 
measured using ELISA. Results are presented as % TNFα of Aβ response 
treated with phosphate buffered saline (PBS) medium. Error bars represent 
SE for n= 18 trials (6 separate experiments) for TLR2, TLR1, TLR6, and n = 
6 trials (2 separate experiments) for TLR2/TLR1 and TLR2/TLR6. A 
Student’s t-test was used to calculate the significance between individual 
TLR and the rat IgG isotype control ( *p < 0.001). rIgG; rat IgG 
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reduction for TLR1 neutralization compared to 43% for TLR6 blockade. The Aβ signal 
was further decreased when the combination of TLR2/TLR1 or TLR2/TLR6 were 
blocked. Neutralization of TLR2/TLR1 complex decreased the % response to 24.7 ± 
2.43, while TLR2/TLR6 complex blockade lowered the % response to 33.77 ± 2.04. A 
slight enhancement of Aβ response was observed for cells pre-incubated with 20 μg/ml of 
TLR isotype rat IgG control. Overall, the presented results demonstrated that TLR2 and 
TLR4 have an active role in Aβ-induced activation of the innate immune response. 
Additionally, our recent data also suggests a possible involvement of TLR1 and TLR6 as 
well for Aβ activation of downstream TLR signaling. 
 
4.2.2. Mammalian Cell System: Human Embryonic Kidney (HEK) cells 
 
4.2.2.1 Induction of proinflammatory IL-8 production in transfected HEK 293 cells with 
known TLR agonists 
 
The main purpose of the study is to determine which TLR is responsible for Aβ-
dependent inflammatory response. Using THP-1 monocytes, we have identified TLR2 
and TLR4 to have a role in Aβ activation of the innate immune response. Numerous 
investigators whose focus is to study the mechanisms involved in TLR recognition and 
signaling utilize model cell lines such as Human embryonic kidney (HEK) cells (Bauer; 
Chen et al., 2006; Walter et al., 2007; Goodridge and Underhill, 2008). We have started 
utilizing HEK293 cells to further investigate the role of TLR2 and its complex (TLR2/1 
or TLR2/6) in Aβ proinflammatory response. This mammalian cell line does not express 
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TLR2 and other TLRs (Razonable et al., 2006), although recent studies have shown that 
HEK293 cells express low amounts of TLR1 and TLR6 (InvivoGen, 2006). We have 
acquired human HEK293 cells transfected with TLR2 (herein referred to as HEK 
293hTLR2) to substantiate the role of TLR2 in Aβ response. For proper interpretation of 
results, we have also acquired non-transfected HEK293 cells (herein referred to as null 
HEK293).  
We began our investigation by first testing the ability of our known TLR agonists 
to induce IL-8 production in our HEK293 cell lines (Figure 4.10). HEK 293hTLR2 cells 
were strongly stimulated to produce IL-8 in the presence of 1 ng/ml of Pam3CSK4 
(TLR2/1 ligand) or 1 ng/ml of FSL-1 (TLR2/6 ligand) (Figure 4.10b). Expectedly, our 
ultrapure LPS (TLR4 ligand) failed to stimulate our TLR2 transfected cells in producing 
IL-8. Null HEK293 cells, on the other hand, were not stimulated by same concentration 
of the known TLR agonists (Figure 4.10a). The data presented here signify that the 
acquired TLR2-transfected HEK 293 cells are devoid of any traces of TLR4, and our 
Null HEK293 cells may be used for succeeding experiments as control cells.  
We wanted to know if our TLR neutralization assay can also be applied to our 
HEK 293hTLR2. HEK 293TLR2 cells were grown, as described in Methods. Cells were 
pre-treated with 10 μg/ml of the TLR antibodies or isotype rat IgG control for 1 hour 
prior to 24-hour stimulation with either 1 ng/ml of Pam3CSK4 or 1 ng/ml of FSL-1. After 
post-stimulation, IL-8 levels were measured by ELISA. Our results confirmed the 
effectiveness of the TLR neutralization assay on this cell line. Antibody blockade of 
TLR2 or TLR1 decreased the Pam3CSK4-induced IL-8 response to 30.9 ± 0.84 and 20.9 
± 1.34, respectively (Figure 4.11). These signify a 48% reduction for TLR2, and 58% 
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Figure 4.10. PAMP activity on HEK 293 cells. (A) Activity 
of PAMPs on Null HEK293 cells. Cells were grown, as 
described in Methods, prior to 24-hour stimulation with known 
TLR PAMPs. Concentration of the agonists are E. coli K12 
LPS (10 ng/ml), Pam3CSK4 (1 ng/ml), and FSL-1 (1 ng/ml). 
(B) Stimulation of TLR2-transfected HEK 293 cells (HEK 
293hTLR2) with known TLR agonists. Concentration of 
agonists is the same as in A. For both instances, secreted IL-8 
was measured by ELISA. These results represent 1 
representative experiment of 4. Error bars represent SE of n= 3 
trials (1 experiment)  
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Figure 4.11. TLR2 complex antibody neutralization of TLR2 ligands. HEK 
293hTLR2 cells were pre-incubated with 10 μg/ml of TLR2, TLR1, TLR6 
(InvivoGen) antibodies, or 20 μg/ml rat IgG isotype control for 1 hour, as 
described in Methods. After pre-treatment, HEK 293hTLR2 cells were 
stimulated with 1 ng/ml of either Pam3CSK4 or FSL-1 for 24 hours. IL-8 was 
measured using ELISA. Results are presented as % IL-8 of Pam3CSK4 or FSL 
response treated with phosphate buffered saline (PBS) medium. Error bars 
represent SE for n= 6 trials (2 separate experiments) for Pam3CSK4 and n = 3 
trials (1 experiment) for FSL-1. rIgG; rat IgG 
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reduction for TLR1, compared to the rat IgG isotype control. TLR6 blockade evoked a 
28% attenuation of Pam3CSK4 response. However, this attenuation was comparable to 
that of the rat IgG isotype control (22% reduction). Antibody neutralization of the 
TLR2/TLR6 agonist FSL-1 was clear. TLR2 neutralization almost completely abrogated 
FSL-1- induced IL-8 response (85% reduction) while TLR6 blockade lowered the FSL-1 
response by 57% (% response of 42.8 ± 3.13). TLR1 neutralization did not have an effect 
on the FSL-1 response. For all neutralization experiments, we have included stimulation 
of null HEK293 cells with the TLR agonists. Similar to Figure 4.10, 1 ng/ml of 
Pam3CSK4 or FSL-1 did not induce IL-8 production in null HEK 293 cells. 
 
4.2.2.2 Induction of proinflammatory IL-8 production in transfected HEK 293 cells with 
fibrillar Aβ(1-42) 
 
 To understand the contribution of TLR2 in Aβ-induced immune response, and to 
assess the responsiveness of the HEK cells to Aβ, we next stimulated our HEK 293 cells 
with 15 μmol/L of Aβ(1-42). Null HEK 293 cells and HEK 293hTLR2 cells were grown, 
as described in Methods. After 4 hours of allowing the cells to adhere in the cell culture 
plate, cells were stimulated with 15 μmol/L of Aβ(1-42) for 24 hours. The IL-8 level was 
measured post-stimulation by ELISA. As seen in Figure 4.12, TLR2-transfected HEK 
cells produced a significant amount of IL-8 (81 pg/ml/106 cells ± 1.8), while null HEK 
cells failed to produce IL-8 upon Aβ stimulation.  This result further substantiates our 
finding that TLR2 plays a role for Aβ-induced proinflammatory production. 
We carried out the TLR antibody neutralization to further verify the role of TLR2, 
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as well as TLR2 complex, in Aβ response. We pre-treated our Null HEK cells and HEK 
293hTLR2 cells with 10 μg/ml of TLR antibodies (InvivoGen) or rat IgG isotype control 
(Sigma) for 1 hour prior to 24-hour cell stimulation with 15 μmol/L of Aβ(1-42). As 
expected, Aβ treatment did not stimulate our null HEK cells in producing IL-8. Our 
initial results with the HEK 293TLR2 cells (data not shown) revealed a big reduction in 
Aβ-IL-8 response when TLR1 was neutralized (70% reduction). A 30% reduction was 
also observed when TLR2 and TLR6 were blocked. However, there was a substantial 
attenuation of Aβ response when cells were pre-treated with the isotype IgG control. This 
issue of reduced Aβ response with IgG control made it impossible to interpret our TLR 
neutralization results properly. The TLR neutralization of Aβ-induced IL-8 response in 
HEK 293TLR2 is an ongoing investigation in our lab and the effect of isotype IgG 
control needs further analysis.  
 
4.3. Discussion 
 
The data that we have presented in this study emphasize the role of toll-like 
receptors in Aβ-induced activation of the innate immune response. By utilizing THP-1 
monocytes which naturally express TLRs ((Faure et al., 2000), we have identified TLR4 
and TLR2 to be involved in proinflammatory response initiated by fibrillar Aβ(1-42). 
These results were consistent with that of Fassbender and colleagues (Fassbender et al., 
2004). Using an antibody neutralization assay, they reported a CD14-dependent 
microglial activation by fibrillar Aβ. Moreover, they presented Aβ activation by nuclear 
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Figure 4.12. Fibrillar Aβ(1-42) activity on HEK 293 cells. Null HEK293 
cells and TLR-2 transfected HEK293 cells (HEK 293hTLR2) were grown, as 
described in Methods, prior to 24-hour stimulation with 15 μM of Aβ 
aggregated at 216 hours. Secreted IL-8 was measured by ELISA. This result 
represent 1 representative experiment of  3. Error bars represent SE of n= 3 
trials (1 experiment)  
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translocation of NFκB in CD14-transfected Chinese hamster ovary (CHO-K1) cells. 
Since the CHO cells lack a functional TLR2, they suggested that TLR4 may be 
responsible for Aβ signal transduction.  
Our TLR antibody neutralization in THP-1 monocytes clearly demonstrated the 
importance of TLR4 in Aβ-induced immune response (Figure 4.5, 4.6b, 4.7). A 
consistent 50-60% reduction of the Aβ-induced TNFα response was observed when cells 
were pre-incubated with TLR4 antibody. Additionally, we identified TLR2 to be equally 
responsible for fibrillar Aβ response. In fact, our results showed a more significant 
reduction of Aβ response from TLR2 antibodies than from TLR4 antibodies (Figure 4.5, 
4.6b). We have further substantiated our finding that TLR2 is involved in fibrillar Aβ-
induced immune response by using a TLR2-transfected cell line. HEK cells do not 
express TLR2 (Razonable et al., 2006), thus it is a model system in further clarifying the 
importance of TLR in agonist signaling. Stimulation of HEK 293hTLR2 with 15 μmol/L 
of Aβ resulted in the production of proinflammatory IL-8, while the same concentration 
of Aβ failed to stimulate the Null HEK293 cells for IL-8 production (Figure 4.12). This 
result implies that the transfected TLR2 gene was responsible for Aβ-induced IL-8 
response. 
Our results have also indicated that TLR2 and TLR4 may compensate for each 
other for transduction of Aβ signal when necessary (Figure 4.7). Moreover, we have 
further demonstrated the importance of CD14 on the Aβ-induced activation of 
downstream signaling (Figure 4.5, 4.6a, 4.7). One difficulty that we encountered using 
TLR neutralization of Aβ response is a consistent stimulation of TNFα response for 
CD14 isotype control, IgG1 (Figure 4.5, 4.6a). This 20-30% increase in signal may have 
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offset the effectiveness of our anti-CD14 neutralization. These issues emphasize the 
importance of including the isotype controls in the experiment for proper and accurate 
interpretation of results.  
Several groups have started to focus on Toll-like receptors and its accessory 
proteins to better understand the mechanism of Aβ inflammatory response or clearance. 
Using cultured CD14-positive microglia and microglia derived from CD14-deficient 
mice, Liu et al emphasized the importance of CD14 in Aβ(1-42) phagocytosis by 
microglia (Liu et al., 2005). In vivo studies using Mo/Hu APPswe PSIdE9 mice deficient 
in TLR4 showed a decreased clearance of diffuse and fibrillar Aβ deposits, demonstrating 
the significance of TLR4 signaling pathway in Aβ load and clearance in AD brain 
(Tahara et al., 2006).  Furthermore, using immunohistochemical staining, Liu et al. 
reported a strong expression of CD14 on brain sections of AD patients as compared to 
that of control subjects (Liu et al., 2005). Recently, Fassbender’s group also released their 
findings that TLR4-deficient mice C3H/HeJ strongly inhibited monocytic and microglial 
activation by aggregated Aβ(1-42) as demonstrated by a significant decrease in the 
secretion of IL-6, TNFα and nitric oxide compared to the wildtype C3H/HeN (expressing 
TLR4) mice (Walter et al., 2007). This result further supported our findings of TLR4-
mediated Aβ proinflammatory response. Similarly, findings by Jin, et al. showed that 
TLR4 was also implicated in the upregulation of proinflammatory (TNFα, IL-1β, IL-10, 
IL-17) products in the brains of TLR4 wildtype AD mice as compared to TLR4 wildtype 
non-transgenic mice (Jin et al., 2008). Recently, Rivest and colleagues have also 
published reports implicating TLR2 an endogenous receptor that is involved in clearance 
of Aβ(1-42) (Richard et al., 2008). Overall, our findings, together with these other 
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studies, contributed to growing evidences linking neurodegenerative diseases with innate 
immune response. 
Investigating the ligand-TLR interaction means that utmost care should be taken 
to ensure that the agonists are free of contamination that might falsely activate certain 
TLRs (Kielian, 2006). Over the years, the purity of TLR agonists has been an ongoing 
issue in investigating agonist-TLR interaction (Hirschfeld et al., 2000; Gao et al., 2001; 
Lee et al., 2002).  We have carefully prepared our Aβ(1-42) samples and made sure that 
our preparations are free of contaminating traces of LPS.  Although the commercial Aβ 
lots were already endotoxin-tested prior to shipment (0.35 EU/mg, which corresponds 
into an effective LPS concentration of 8 pg/ml) (Gao and Tsan, 2003), we still have 
continuously monitored our Aβ preparations using PMX-B. PMX-B is often used in cell 
culture systems to test for LPS contamination (Weaver et al., 2007). Our Aβ preparations 
were devoid of any traces of bacterial LPS contamination, as depicted by Figure 4.2b. 
XTT proliferation assay was also done routinely to verify the purity of our Aβ 
preparations. Moreover, the possibility of contamination in our Aβ preparation was 
invalidated by our Aβ aggregation data (Figure 3.1) which demonstrated a steady 
increase of TNFα production when Aβ was aggregated at 4oC for up to 96 hours, 
followed by a decline of the TNFα signal to baseline level when Aβ was incubated for 
longer period of time (216 hours). This trend would not be observed if traces of 
contaminating TLR ligands are present in our Aβ preparation. Degradation of the 
contaminants is also not expected, thus, if there is a presence of any traces of bacterial 
contaminants, the Aβ-induced TNFα signal should remain at 216 hours.  
Our preliminary results with THP-1 monocytes (Figure 4.9) also suggest a 
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possible role for TLR1 and TLR6 in Aβ activation of the innate immune response. Our 
laboratory, and others, have demonstrated the importance of TLR2 in Aβ-induced 
immune response (Jana et al., 2008; Richard et al., 2008; Udan et al., 2008). TLR2 is 
known to form a heterodimeric complex with either TLR1 or TLR6 for recognition of a 
wide spectrum of ligands (Schroder et al., 2004; Manukyan et al., 2005; Kielian, 2006). 
Our TLR neutralization revealed a significantly decreased TNFα response for Aβ when 
TLR1 and TLR6 were blocked. Interestingly, TLR1 seems to have more effect in Aβ 
response than TLR6, as demonstrated by greater inhibition with 10 μg/ml of TLR1 
antibody as compared to TLR6. We wanted to further investigate the possibility of TLR2 
complex formation for recognition of Aβ by doing antibody neutralization on TLR2-
transfected HEK293 cell line. We are on our preliminary stage of investigation using 
HEK 293 cells, however, rat IgG effects on the Aβ response have been encountered and 
are being carefully assessed. Nevertheless, understanding the role of TLR1 and TLR6 in 
Aβ interaction with TLR2 will give us further insight on Aβ-TLR2 recognition.  
Numerous investigations about structures of TLR-ligand complexes have 
continuously emerged over the years to better understand their activation mechanisms. 
Previous report about the crystal structure of TLR1-TLR2-Pam3CSK4 emphasizes the 
importance of the lipid chains of Pam3CSK4 in its interaction with the TLR2/TLR1 
heterodimers (Jin et al., 2007). The crystal structure showed the interaction of two of the 
three lipid chains of Pam3CSK4 with TLR2 pocket, and the last lipid chain is inserted into 
a hydrophobic channel of TLR1. Likewise, structure studies of LPS-TLR4-MD2 binding 
were done using LPS antagonist Eritoran. LPS is an amphipathic macromolecule 
composed of hydrophobic lipid A, composed of four to seven acyl chains and 
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phosphorylated  di-glucosamine,  core and O-antigen (Chapter 1, Figure 1.5). Eritoran, on 
the other hand, is a structural mimic of lipid A of LPS , with four acyl chains and a 
phosphorylated glucosamine backbone (Mullarkey et al., 2003; Rossignol and Lynn, 
2005). Structural studies of Eritoran-MD2-TLR4 shows binding of Eritoran to the 
hydrophobic pocket of MD-2 via its acyl chains (Kim et al., 2007). Moreover, a crystal 
structure of mouse CD14 shows a large hydrophobic pocket on the N-terminal which was 
identified to be the main component of the LPS-binding site (Kim et al., 2005). A 
structural model of Aβ fibrils by NMR spectroscopy revealed a double- layered β sheet 
structure with a hydrophobic core and a hydrophobic face. It is thus possible that 
hydrophobicity plays a big role in ligand-TLR recognition, and the hydrophobicity 
possessed by Aβ may also be responsible for its recognition by CD14, TLR4 and TLR2. 
The association of Aβ with inflammation is ongoing research in the field of AD. It 
remains to be determined whether inflammatory response is advantageous or detrimental 
to neuron survival. The identification of several receptors on microglia and monocytes 
that recognize fibrillar Aβ has opened new venues for understanding the mechanism of 
Aβ and inflammatory response. The inclusion of TLRs in the list of receptors that 
recognize Aβ contributes to the role of innate immunity in the pathogenesis of AD, and 
therefore may be a powerful tool for identification of therapeutic targets that slow the 
progression of AD. 
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5 THE ROLE OF MONOCYTE MATURATION AND ITS RELATIONSHIP TO  
AMYLOID BETA AND INFLAMMATION 
 
5.1 Introduction 
 
The presence of of activated microglia surrounding neuritic plaques in the AD 
brain strongly suggests a specific interaction between Aβ and microglia. Moreover, 
numerous evidence now shows that microglia may be activated by Aβ, leading to 
initiation of inflammation (Frautschy et al., 1992; Barger and Harmon, 1997; Akama et 
al., 1998; Hu and Van Eldik, 1999). A plethora of inflammatory products in the brain 
upon microglial activation may encourage the transmigration of monocytes from the 
circulation across the blood-brain barrier. Thus, the peripheral monocytes, which 
differentiate into macrophages during the infective process, may also be present as 
infiltrated phagocytes along with the resident microglia surrounding the senile plaques 
(Fiala et al., 1998). Previous reports have shown that Aβ modulates monocyte adhesion 
(Yan et al., 1996) and differentiation to macrophages (Fiala et al., 1998). Our recent 
finding demonstrating oligomeric Aβ(1-42)- induced THP-1 monocyte maturation and 
adhesion was consistent with these previous reports (Crouse et al., 2009). Furthermore, 
additional studies have documented monocyte/macrophage infiltration to sites of brain 
Aβ accumulation (Simard et al., 2006; El Khoury et al., 2007). Macrophages play an 
important role in inflammation through production of proinflammatory cytokines and 
chemokines, cell adhesion molecules and nitric oxide (NO), among others (Kim et al., 
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2006). Thus, the presence of macrophages in the brain may also contribute to the 
exacerbation of inflammation induced by Aβ.  
To study the contribution of macrophages in Aβ-induced immune response, we 
have modeled the macrophages present in the brain by differentiating our THP-1 
monocytes using phorbol myristate acetate (PMA) (Tsuchiya et al., 1982). We have 
chosen TNFα production as the outcome variable for studying effect of macrophages in 
Aβ-induced proinflammatory production. In this investigation, we report that 
differentiation of THP-1 monocytes to macrophages significantly enhanced TNFα 
production by fibrillar Aβ(1-42), and may further contribute to inflammation in the 
diseased brain.  
 
5.2. Results 
 
5.2.1 TNFα production induced by known TLR agonists in differentiated and 
undifferentiated THP-1 cells 
 
For our initial investigation, we examined the  proinflammatory response of 
PMA-differentiated THP-1 macrophages to known TLR agonists. THP-1 monocytes 
grow in suspension and they do not adhere to the surfaces of the cell culture plates. For 
the induction of differentiation to macrophage-like cells, THP-1 monocytes were treated 
with 10 ng/ml of PMA for 24 hours, as described in Methods. After incubation with 
PMA, THP-1 cells became adherent and developed morphological changes 
characteristics of differentiation to macrophages. The extent of cell adherence was 
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measured by direct counting of the adherent cells and dividing it by the total number of 
plated cells. Cells that were used for subsequent experiments have % adherence values of 
75% and above. Cells that were poorly adherent were not used. Once the % adherence 
was measured, cells were treated with either ultrapure K12 LPS (TLR4 agonist) or 
Pam3CSK4 for 6 hours. Figure 5.1 shows the comparison of TNFα secretion for THP-1 
monocytes or PMA-induced macrophages that were stimulated with 10 ng/ml of 
ultrapure K12 LPS. Although undifferentiated THP-1 cells produced TNFα upon 
stimulation with ultrapure LPS, differentiation of monocytes to macrophages 
substantially elevated the LPS-induced TNFα response five-fold. Moreover, PMA-
differentiated THP-1 macrophages responded to LPS and Pam3CSK4 (TLR2 agonist) 
stimulation in a dose-dependent manner (Figure 5.2). Our data is consistent with that of 
Takashiba (Takashiba et al., 1999). The extent of TNFα secretion varies from one 
experiment to another. This explains the different levels of TNFα when PMA-
differentiated THP-1 monocytes were stimulated with 10 ng/ml LPS (Figure 5.1 and 5.2). 
 
5.2.2 Aβ-induced TNFα production is augmented in PMA-derived THP-1 
macrophages 
 
We next compared the proinflammatory response of Aβ(1-42) in PMA-
differentiated THP-1 cells to that of undifferentiated THP-1 cells. We incubated our 
THP-1 monocytes and PMA-differentiated THP-1 cells with 15 μmol/L of Aβ(1-42) 
aggregated at 4oC for 48 hours. At various incubation times, secreted TNFα was 
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Figure 5.1. LPS-induced TNFα production from differentiated and 
undifferentiated THP-1 cells. THP-1 monocytes were differentiated for 24 
hours using phorbol-myristate acetate (PMA), as described in the Methods. 
After incubation, undifferentiated cells (THP-1 monocytes, black bars) and 
PMA-differentiated cells (macrophages, gray bars) were stimulated with 10 
ng/ml of LPS for 6 hours. TNFα was measured in the supernatant after 
stimulation by ELISA. This result is a represent 1 representative experiment of 
3. Error bars denote n = 3 trials (1 experiment) 
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Figure 5.2. Dose response of TNFα production by known 
TLR agonists. THP-1 monoctyes were differentiated using 
10 ng/ml PMA, as described in Methods. After 
differentiation, PMA-differentiated cells were treated with 
increasing concentration of (A)K12 LPS (TLR4 agonist) or 
(B) Pam3CSK4 (TLR2 agonist) for 6 hours. TNFα was 
measured using ELISA. This result represent 1 
representative experiment of 2. Error bars represent n = 3 
trial (1 experiment). 
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measured. Figure 5.3a demonstrates that Aβ(1-42) stimulated THP-1 monocytes (circle) 
for TNFα production as early as 4 hours incubation (18.9 ± 2.9 pg/ml), with maximal 
response observed at 10 hours (also shown in Figure 3.3a). In comparison, PMA-
differentiated THP-1 (triangles) cells began producing considerable TNFα at 6 hours of 
incubation (27 ± 0.53 pg/ml) and the TNFα continued to rise even at 24 hours post-
stimulation. At this time (24 hours), Aβ-induced TNFα production is three-fold higher in 
PMA-differentiated cells than undifferentiated cells. Like the response of differentiated 
THP-1 cells to known TLR agonists, PMA-differentiated THP-1 cells were also 
stimulated by Aβ(1-42) in a dose-dependent manner (Figure 5.3b).  These results 
demonstrate a more enhanced production of proinflammatory products when 
macrophages are stimulated by fibrillar Aβ(1-42). 
 
5.3 Discussion 
 
Differentiation of THP-1 monocytes to macrophages with phorbol esters have 
been well-characterized (Tsuchiya et al., 1982; Auwerx, 1991; Takashiba et al., 1999; 
Traore et al., 2005).  One of the most widely-used differentiating agent is 4α-phorbol-12-
myristate-13- acetate (PMA) (Chong et al., 2003; Lai et al., 2006).  In this study we have 
analyzed the contribution of macrophages in Aβ-induced proinflammatory production. 
We have shown in this preliminary investigation that TNFα production is considerably 
increased when PMA-derived THP-1 cells were stimulated with known TLR agonists 
LPS(TLR4) and Pam3CSK4 (TLR2) as compared to undifferentiated cells. Similar results 
were observed when PMA-differentiated cells were stimulated with 15μM of Aβ(1-42).  
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Figure 5.3. Fibrillar Aβ(1-42)-induced TNFα secretion 
from differentiated and undifferentiated THP-1 cells. (A) 
THP-1 monocytes (circles) or PMA-differentiated THP-1 
macrophages (triangles) were stimulated for 0, 2, 4,6,10 and 24 
hours with 15 μM Aβ(1-42). After post-stimulation, TNFα was 
measured using ELISA. (B) Dose response of TNFα secretion. 
THP-1 monocytes were differentiated with 10 ng/ml PMA, as 
described in Methods. PMA-derived THP-1 macrophages were 
stimulated with increasing concentration of Aβ(1-42) for 24 
hours. TNFα level was measured by ELISA. For both 
experiments, error bars represent n = 3 trials (1 experiment) 
Aβ incubation time, hrs
0 6 12 18 24
[T
N
Fα
], 
pg
/m
l
0
100
200
300
 
[Aβ(1-42)], μM
2.5 5.0 7.5 10.0 12.5 15.0
[T
N
F α
], 
pg
/m
l
0
200
400
600
800
  155
Takashiba et al investigated the relationship between THP-1 cell maturation and 
mechanism of LPS stimulation. They revealed the novel role for NF-κB in the maturation 
process. They found that differentiation of THP-1 monocytes to macrophages results in 
accumulation of NF-κB in the cytoplasm, which is mainly responsible for the enhanced 
ability of the cell to respond to LPS stimulation (Takashiba et al., 1999). This suggests 
that accumulation of NF-κB in the cytoplasm upon maturation of monocytes to 
macrophages primes the cells for increased responsiveness to LPS and in turn, leads to 
rapid secretion of inflammatory mediators.  
Recent reports showed that cytokine gene transcription by Aβ requires stimulation 
of NF-κB pathway (Combs et al., 2001). The accumulation of NF-κB in the cytoplasm 
during the differentiation process may thus be correlated to enhanced production of 
TNFα upon Aβ stimulation. Another possibility for elevated TNFα production in 
macrophages is the constitutive expression of TLRs. Although the level of TLR2 in 
macrophages that were derived in vitro is similar to that of monocytes, TLR4 expression 
was significantly increased by about 300% in macrophages when compared to monocytes 
(O'Mahony et al., 2008). We have previously demonstrated the role of TLR2 and TLR4 
in Aβ-induced inflammatory production (Udan et al., 2008) (Chapter 4). A combination 
of elevated TLR and NF-κB expression in macrophages may be responsible for enhanced 
proinflammatory production by Aβ. 
Several studies have shown a correlation between Aβ accumulation and 
infiltration of peripheral blood monocytes/macrophages in senile plaques (Fiala et al., 
1998; Simard et al., 2006; El Khoury et al., 2007). Oligomeric Aβ(1-42) has likewise 
been reported to have chemotactic activity (Giri et al., 2000; Le et al., 2001). Moreover, 
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our lab has reported that oligomeric Aβ(1-42) aggregates induce THP-1 monocyte 
differentiation to macrophages (Crouse et al., 2009).  These evidences suggest that 
oligomeric Aβ(1-42) may also induce recruitment of blood-derived macrophages to the 
site of inflammation.  
The correlation between Aβ and inflammation in AD brain is an active focus of 
investigation. Our preliminary data suggests that Aβ-induced heightened inflammation 
may be mediated by TLRs from resident activated microglia as well as infiltrating 
macrophages that may also be present surrounding the senile plaque. Further 
investigations need to be performed to further clarify the mechanism of Aβ-induced 
immune response and to better understand the contribution of immune cells in AD 
pathogenesis. 
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6 CONCLUSION 
 
 In these studies, we successfully demonstrated that Aβ(1-42) invoked 
proinflammatory response in human THP-1 monocytes/ macrophages, a mammalian cell 
model system for human microglia. Moreover, the data presented suggest that the ability 
of Aβ to induce TNFα production is dependent on its aggregation conformation. Using a 
combination of AFM and cellular studies, along with high speed centrifugation of Aβ 
samples and employing conformation-specific antibodies, we reported that the soluble yet 
fibrillar Aβ species are the bioactive Aβ. These Aβ species exist prior to formation of 
longer, more mature fibrils, and are thus called fibrillar precursors.  
 Studying Aβ fibrillogenesis is a very challenging task. Although microscopy 
(AFM and EM) are valuable tools in studying the morphology of the formed Aβ species, 
this technique alone could not provide detailed information of the fibril size for different 
aggregation species nor is appropriate for real time analysis. In order to have a better 
understanding of the bioactive Aβ(1-42) species, the use of other biophysical techniques 
that will further provide vital information such as molecular weight and conformation, 
along with the microscopy studies, may aid in elucidating the Aβ(1-42) species that can 
activate our THP-1 cells.  
We also showed the correlation between Aβ and the innate immune response by 
identifying the involvement of toll-like receptors, particularly TLR4 and TLR2, in Aβ-
induced response. Our findings further suggest that TLR4 and TLR2 may compensate for 
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one another for Aβ-induced activation of TLR downstream signaling. Moreover, the 
possibility of Aβ utilizing TLR2/TLR1 or TLR2/TLR6 complex was also suggested 
based on a significant neutralizing effect of the TLR1 and TLR6 antibodies on Aβ 
response. The possible involvement of the TLR2/1 or TLR2/6 in Aβ-induced immune 
response is a good are to follow up on for the information that can be obtained will give 
us further insight on Aβ-TLR2 recognition. Aside from the TLR neutralization assay, the 
role of TLRs in Aβ-induced inflammatory response may be confirmed by other methods 
such as using cell lines transfected with TLR as well as utilizing TLR knockout mice. 
These are valuable tools for studying the ligand-TLR interaction.  
Our results also showed that Aβ-induced TNFα production for PMA-induced THP-1 
macrophages is undoubtedly much higher compared to that of THP-1 monocytes.  This 
suggests that infiltrating macrophages that may be present surrounding the senile plaque 
may also contribute to heightened inflammation that is observed in the AD brain.  
Overall, we presented evidences suggesting that inflammation in the AD brain is 
induced by soluble yet fibrillar species of Aβ(1-42), and the heightened inflammation 
observed in microglia surrounding the AD senile plaques may in part be due to the 
contribution of Aβ interaction with TLR2 and TLR4 that are expressed on microglia, as 
well as the infiltrating macrophages that may be present in the site of injury. This study 
has thus opened new venues for understanding the mechanism of Aβ-induced 
inflammatory response and may be a new therapeutic target for AD. 
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